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ABSTRACT 
 
Ghrelin is a 28 amino acid peptide that interacts with ghrelin receptors (GHS-Rs) to modulate 
brain reinforcement circuits. Systemic ghrelin infusions augment cocaine (COC) stimulated 
locomotion and conditioned place preference (CPP) in rats, whereas genetic or 
pharmacological ablation of GHS-Rs has been shown to attenuate the acute locomotor-
enhancing effects of nicotine (NIC) and COC, and to blunt the CPP induced by food, alcohol, 
amphetamine and COC in mice. The stimulant NIC can induce CPP and like COC, repeated 
administration of NIC induces locomotor sensitization in rats. In experiment 1, we examined 
the effects of GHS-R antagonism with JMV 2959 on COC-induced locomotion and found 
that JMV 2959 suppresses COC-induced locomotor sensitization.  In experiment 2, we 
examined the effects of GHS-R antagonism with JMV 2959 on NIC-induced locomotion and 
found that JMV 2959 suppresses NIC-induced locomotor sensitization.  In experiment 3, we 
examined the effects of GHS-R knockout on COC-induced locomotion and found that 
animals sustaining GHS-R knockout display a suppression of COC-induced locomotor 
sensitization.  In experiment 4, we examined the effects of GHS-R knockout on COC-
induced locomotion and found that animals sustaining GHS-R knockout display a 
suppression of COC-induced locomotor sensitization.  In experiment 5, we examined the 
effects of JMV 2959 on NIC-enhanced intracranial self-stimulation (ICSS) responding and 
found that JMV 2959 alone had no effect, but when combined with NIC,JMV 2959 
pretreatment reversed the enhancement of responding produced by NIC.  In experiment 6, we 
examined the effects of GHS-R knockout on ICSS responding and found that animals 
sustaining GHS-R knockout were unable to acquire ICSS at current intensity levels that 
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would support responding by WT animals.  It was not until the intensity was ramped up four 
fold that these knockout rats were able to acquire responding.  These results show that 
antagonism of GHS-Rs diminishes the reinforcing effects of NIC and COC.  This provides 
evidence that antagonists of GHS-Rs could be useful in the treatment of drug addiction, 
particularly that involving nicotine.  
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NOMENCLATURE 
ACTH .......................................................................................... adrenocorticotrophic hormone 
ARC .................................................................................................................... arcuate nucleus 
COC ................................................................................................................................ cocaine 
CPP ............................................................................................... conditioned place preference 
DA ................................................................................................................................ dopamine 
GHS-R................................................ growth hormone secretagogue receptor, ghrelin receptor 
GHS-R(-/-) ........................................................................................... ghrelin receptor knockout 
GOAT .................................................................................................. ghrelin o-acyltransferase 
ICSS ................................................................................................ intracranial self-stimulation 
ICV .......................................................................................................... intracerebroventricular 
i.m. ....................................................................................................................... intra-muscular 
i.p. ....................................................................................................................... intra-peritoneal 
MFB ...................................................................................................... medial forebrain bundle 
NAC ..............................................................................................................nucleus accumbens 
NIC .................................................................................................................................. nicotine 
NPY..................................................................................................................... neuropeptide Y 
POMC ........................................................................................................ proopiomelanocortin 
PVN...................................................................... paraventricular nucleus of the hypothalamus 
VTA ......................................................................................................... ventral tegmental area 
WT ................................................................................................................................wild type 
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CHAPTER I 
INTRODUCTION* 
 
In recent years, a significant amount of research has been dedicated to finding a 
solution to the problem of obesity.  One of the major health concerns in the United States as 
well as other Western European societies is obesity.  The prevalence of obesity is increasing 
(Olshansky et al., 2005).  By the year 2035, if the current progression continues, it is 
estimated that some 90% of Americans will be obese (Garko, 2011).  One line of obesity-
related research has focused on the factors that stimulate eating (Wren et al., 2000), while 
another has focused on the factors that inhibit eating.  From this research came the discovery 
of ghrelin, a 28 amino acid peptide secreted from the stomach and gut.  Initially, ghrelin was 
found to be an endogenous ligand for the growth-hormone secretagogue receptors (GHS-Rs), 
which are responsible for releasing growth-hormone from the pituitary (Kojima et al., 1999, 
Kojima and Kangawa, 2005).  It wasn’t long after ghrelin’s discovery that ghrelin was 
detected in a large number of other areas in the body and that it plays a role in a considerable 
range of functions.  It’s important to note the fact that ghrelin is the only known peripheral 
peptide that stimulates food intake (Wren et al., 2000).  From an obesity perspective, 
treatments that diminish ghrelin function might be useful for reducing food intake. 
 Although ghrelin was originally identified in the stomach, it was also later detected in 
a number of brain regions (Kojima et al., 1999).  Ghrelin acts on GHS-Rs which are also 
found in numerous areas of the body and several areas of the brain.  The principal areas 
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where GHS-Rs have been localized are along the vagus nerve and in brain areas that include 
the ventral tegmental area (VTA), hippocampus, arcuate nucleus (ARC) of the hypothalamus, 
nucleus accumbens (NAC), amygdala, and even the Edinger-Westphal nucleus which lies 
just dorsal to the VTA (Kaur and Ryabinin, 2010).  Systemic ghrelin is thus positioned to 
alter vagus nerve signaling to the brain and to enter the brain to act on GHS-Rs. 
 As mentioned earlier, ghrelin binds to GHS-Rs to release growth-hormone from the 
pituitary, but ghrelin and GHS-Rs have also been associated with several other functions.  
Endogenous ghrelin plays an important role in stimulating food intake and inducing growth 
(Wren et al., 2000, Wren et al., 2001a, Depoortere, 2009).  In addition to systemic ghrelin, 
intracerebroventricular (ICV) injections of ghrelin significantly increase food intake 
(Nakazato et al., 2001).  Along with growth induction and feeding behavior, ghrelin has been 
implicated in memory retention and anxiety (Carlini et al., 2002).  Recently, there have been 
studies determining that ghrelin plays a role in metabolic control and that the peptide 
increases gastric emptying (Tschop et al., 2001).  Ghrelin also acts through GHS-Rs to 
moderate the stress response and to modulate energy homeostasis (Abizaid et al., 2006a). 
 The observation that ghrelin induces eating led to a search for GHS-R antagonists that 
might be of use to decrease food intake as a potential means to fight obesity.  However, 
ghrelin is currently being studied in a variety of ways, by itself, and in combination with 
drugs of abuse for its role in mediating reward.  There are two different methods of approach 
to investigating the impact of ghrelin on reward:  ghrelin activation, and ghrelin system 
inactivation.  Within these approaches, there lies a wide range of methods which themselves 
also employ an array of techniques. 
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 Ghrelin administration increases motivation to acquire preferred foods (Fulton, 2010) 
while decreasing water intake (Hashimoto and Ueta, 2011).  In locomotor tests, 
administration of ghrelin has been found to slightly increase locomotion and to enhance the 
hyperactivity produced by psycho-stimulants such as cocaine (COC) (Wellman et al., 2005).  
Ghrelin administration alone and coupled with psycho-stimulants have both been shown to 
increase accumbal dopamine (DA) overflow (Jerlhag et al., 2006).  Also, ghrelin acts to 
facilitate food-induced conditioned place preference (CPP) and even low ghrelin doses 
augment COC-generated CPP (Davis et al., 2007, Perello et al., 2010). 
While little work has been done with ghrelin and addictive drug self-administration, 
serum levels of ghrelin have been shown to rise preceding periods of reinstatement for COC 
(Tessari et al., 2007).  Surprisingly, in an intracranial self-stimulation (ICSS) task, wherein 
rats press a lever for a pleasurable electrical stimulation of their brain at varying frequencies, 
ghrelin decreases responding causing a rightward shift (unpublished observations) yet, GHS-
R antagonists either do not change or increases responding producing a slight leftward shift 
(Wellman et al., 2012).  Ghrelin administration, centrally or peripherally, has also been 
shown to produce wakefulness and arousal (Korotkova et al., 2006), as well as having the 
capacity to alter circadian rhythm (Yannielli et al., 2007).   
 In order to examine the effects of inactivation of ghrelin, researchers have used 
similar tests to the ones mentioned above for examining the effects of ghrelin administration.  
There are two main methods of inactivating the ghrelin system.  The least complicated 
approach is through the use of GHS-R antagonists, predominantly a compound known as 
JMV 2959 (Moulin et al., 2007b, Salome et al., 2009b).  The other primary method of 
inactivating the ghrelin system is to genetically knockout the production of ghrelin or to 
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knockout the development of GHS-Rs altogether (Zan et al., 2003).  GHS-R knockout 
animals display reduced locomotor responses to COC (Abizaid et al., 2011).  Since GHS-Rs 
have been found on the vagus nerve, one other avenue of research is to investigate the effects 
of vagotomy on the ghrelin system (Williams et al., 2003).  Subdiaphragmatic vagotomy 
prevents the increase in ghrelin levels in response to food deprivation conditions.  RNA 
silencing and immunosuppression of GHS-Rs are other viable techniques which have yet to 
be fully explored (Lu et al., 2009, Shrestha et al., 2009).  Finally, it may be possible to block 
the formation of active ghrelin.  Blockade of ghrelin o-acyltransferase (GOAT), which is 
required to form active ghrelin, may diminish circulating levels of the active form of this 
peptide (Takahashi et al., 2009).  The term “ghrelin” refers to the octanoylated form of 
ghrelin (acyl ghrelin). 
 The GHS-R was first identified in 1996 and labeled as a pathway for controlling the 
release of growth hormone (Howard et al., 1996).  These receptors, which are g-protein 
coupled receptors, react to small molecules called growth-hormone secretagogues (GHSs) 
and exert action via second messengers.  As such, these receptors were understandably 
termed GHS receptors (GHS-Rs), which were recently designated more specifically as GHS-
R1a.  There is also a GHS-R1b, but this receptor hasn’t been shown to react to ghrelin 
signaling (Howard et al., 1996).  G-protein coupled receptors act by causing different 
downstream effects in various cellular systems when their ligands bind to them.  In the case 
of GHS-Rs, the activity is believed to be through the Gq phospholipase C pathway where 
phospholipase C helps generate diacyl glycerol (DAG) and inositol triphosphate (IP3) from 
phosphatidylinositol 4,5-bisphosphate (PIP2) (Holst et al., 2003, Holst et al., 2004).  Acting 
as a second messenger, DAG activates Protein Kinase C (PKC).  IP3 induces phosphorylation 
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of some proteins (Alberts et al., 2002).  Given that these effects ultimately increase calcium 
levels within neurons, it would not be surprising that activation of GHS-Rs is mostly 
excitatory (Takano et al., 2009) but in at least one system (dorsal raphe), ghrelin is inhibitory 
(Hansson et al., 2011). 
 It is interesting to note however, that at the time of the receptor’s discovery the 
endogenous ligand was yet unknown.  It was discovered a short time later that these 
identified receptors responded to a different unknown compound other than growth hormone 
releasing hormone which led to the later identification of the ghrelin peptide (Bennett et al., 
1997). 
 
 
 
 
 
Figure 1.  Structure of ghrelin (Kojima and Kangawa, 2005). 
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 The ghrelin peptide was discovered by Kojima’s group in 1999, while they were 
investigating the GHS-Rs in the pituitary that act to release growth hormone.  This group was 
able to isolate and identify an endogenous ligand for these GHS-Rs.  The newly identified 
peptide  was named ghrelin, since the root of the word “ghre” means “grow” (Kojima et al., 
1999).  Ghrelin (see Figure 1) is composed of 28 amino acids with the octanoylation of the 
third serine, which is done by GOAT (Yang et al., 2008).  This octanoylation is necessary to 
stimulate release of growth hormone since the acylated form is the most active.  Human 
ghrelin is almost identical to the ghrelin found in rats, having only a two amino acid 
difference (Kojima et al., 1999).  
 Ghrelin is widely distributed throughout the body and the brain but is primarily 
secreted from the fundus of the stomach and is transported across the blood brain barrier and 
into the brain (Wren et al., 2001a, Banks et al., 2002).  Although mostly identical to human 
ghrelin, mouse ghrelin differs in that it can only be transported across the blood brain barrier 
from blood to brain and not back across.  This is likely due to the slight structural differences 
between human and mouse ghrelin.  GHS-Rs are also distributed within the brain as well as 
in the peripheral nervous system (Wren et al., 2001a, Banks et al., 2002). 
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The first GHS-Rs found were detected in the pituitary, as mentioned previously 
(Kojima et al., 1999).  Subsequent studies reported receptors responding to ghrelin in the 
hippocampus and the ventral tegmental area (VTA) (Guan et al., 1997, Abizaid, 2009).  In 
the VTA, ghrelin stimulates feeding behavior and may also affect metabolism.  DA cells in 
the VTA also respond to insulin and leptin, which are well known metabolic hormones 
(Naleid et al., 2005, Abizaid, 2009, van Zessen et al., 2012).  VTA neurons receive inputs 
from orexin neurons in the lateral hypothalamus (Richardson and Aston-Jones, 2012), which 
are also sensitive to ghrelin (see Figure 2).  In the hippocampus, ghrelin promotes long-term 
potentiation (Diano et al., 2006, Banks et al., 2008) and increases memory retention as 
measured by increases in latency in a step-down passive avoidance of foot shock test.  It can 
Figure 2.  VTA – NAcc Pathway (Morikawa and Paladini, 2011). Red lines represent 
DA, green represent glutamate, blue represent GABA, and yellow represents 
norepinephrine. 
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also cause anxiety as shown by decreases in entries into open arms of the elevated plus maze 
and an induction of freezing (Carlini et al., 2002, Hansson et al., 2011). 
Ghrelin and GHS-Rs have been identified in the ARC of the hypothalamus, where 
ghrelin triggers the release of peptides and neurotransmitters.  This release influences food 
intake and plays a role in controlling energy homeostasis (Bagnasco et al., 2003, Cowley et 
al., 2003).  Harrold et al. examined the location of GHS-Rs within the hypothalamus using 
immunohistochemistry to identify Fos expression linked to GHS-Rs.  They found the ARC 
nucleus to be the area with the densest collection of GHS-Rs (Harrold et al., 2008).  Ghrelin 
alters ARC inputs by augmenting neuropeptide Y (NPY) signaling, which stimulates food 
intake and ghrelin diminishes proopiomelanocortin (POMC) signaling.  POMC signaling 
plays a role in the induction of satiety (Cowley et al., 2003).  Systemic infusions of ghrelin 
leads to an increase in Fos in the ARC nucleus, which is expressed where neurons fire action 
potentials making Fos a marker for increases in neuronal activity (Scott et al., 2007).  Ghrelin 
neurons have been located projecting from the hypothalamus to the brainstem, where they 
interact with the dorsal vagal complex. Ghrelin can act as a neurotransmitter, perhaps 
through stimulation of calcium signaling (Hou et al., 2006, Hori et al., 2008). 
Ghrelin also acts on receptors in other areas of the brain, such as the NAC  which is 
well known for playing a role in reward (Quarta et al., 2009).  This area will be more 
important later in the review when ghrelin and reward is addressed directly.  Ghrelin also 
binds to receptors in the amygdala, establishing a role for ghrelin in the emotional aspect of 
feeding and perhaps emotion per se (e.g. fear and anxiety) (Malik et al., 2008).  GHS-Rs 
have also been identified in the Edinger-Westphal nucleus, and ghrelin within this region 
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may play a role in the facilitation of alcohol consumption (Zigman et al., 2006, Kaur and 
Ryabinin, 2010). 
Ghrelin has been shown to play a role in a wide variety of processes throughout the 
body.  Ghrelin binds to GHS-Rs in the ARC nucleus and the hypothalamus to stimulate 
secretion of growth hormone (Wren et al., 2000, Mano-Otagiri et al., 2006).  Intraperitoneal 
(i.p.) administration of 30 nMol ghrelin increases growth hormone levels, and ICV 
administration of 2 nMol ghrelin causes release of adrenocorticotrophic hormone (ACTH) 
(Wren et al., 2000).   
It has been well established that ghrelin is a systemic peptide and the only one known 
to increase food intake.  For example, chronic ghrelin administration induces overeating and 
can lead to obesity when animals are fed a high fat, diet while antagonism of GHS-Rs 
reduces gastric emptying and leads to losses of body weight (Asakawa et al., 2003).  
Endogenous ghrelin levels rise and fall in a diurnal pattern reaching their peaks immediately 
before dark and light periods when gastric content is at its lowest (Murakami et al., 2002).  
Ghrelin levels rise in the absence of food and fall following feeding when on a free feeding 
schedule, but these fluctuations can be altered by inducing “set” meal times.  Anticipation of 
a large meal, like that seen in human feeding patterns, results in higher peak levels of ghrelin 
prior to feeding (Drazen et al., 2006).  Higher acyl ghrelin levels have been associated with 
faster gastric emptying, perhaps through facilitation of gastric motor function (Tschop et al., 
2001).  Des-acyl ghrelin, the inactive form of ghrelin, has been shown to decrease the rate of 
gastric emptying and patients suffering from gastrointestinal disorders have displayed lower 
acyl ghrelin levels than do  healthy patients (Ogiso et al., 2011).   
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Most studies that have examined the biological function of ghrelin have done so by 
examining the effects of administration of exogenous ghrelin.  In Siberian hamsters, systemic 
administration of ghrelin induces the same increases in food hoarding and foraging as seen 
under periods of food deprivation while also stimulating food intake (Keen-Rhinehart and 
Bartness, 2005).  This is interesting because food deprivation results in very small increases 
in food intake or results most often in no increase at all in hamsters (Keen-Rhinehart and 
Bartness, 2005).  Systemic (i.p.) administration of 6 nMol ghrelin induces an increase in food 
seeking behaviors similar to that seen in animals following 24 hour food deprivation 
(Davidson et al., 2005).    
One way that ghrelin has been found to induce stimulation of feeding is by 
phosphorylation of  cAMP response element-binding protein (CREB) to inhibit the effect of 
cholecystokinin (CCK) which effects COC- and amphetamine-regulated transcript (CART) 
in vagal afferent neurons (de Lartigue et al., 2007).  Peripheral ghrelin administration at 10 
nMol causes an increase in Fos expression in the ARC nucleus, which can also be seen 
during periods of food deprivation suggesting that ghrelin is excitatory for eating (Ruter et 
al., 2003, Becskei et al., 2008).  In addition to Fos induction within the ARC nucleus, 
peripheral ghrelin (10 nMol) administration increased Fos expression in the paraventricular 
nucleus of the hypothalamus (PVN) (Ruter et al., 2003).  The PVN is a focal region for the 
induction of eating (Leibowitz, 1978).  Injecting the unacylated form of ghrelin i.p., desacyl 
ghrelin, causes an increase in Fos expression in the ARC nucleus.   Desacyl ghrelin also 
blocks the stimulatory effect on feeding of acyl ghrelin when administered simultaneously  
(Inhoff et al., 2008).  This lends some evidence that Fos activation might not be related to the 
feeding effect of ghrelin.  High plasma levels of desacyl ghrelin have been linked to 
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reductions of food intake and stimulation of adipogenesis (Inhoff et al., 2009).  Ghrelin 
amplifies DA signaling in neurons expressing GHS-Rs and the DA D1 receptor subtype 
(Jiang et al., 2006).  This will be important for understanding the biological function of 
ghrelin with regards to reward.  Injection of ghrelin directly into the VTA and the NAC both 
result in stimulation of food intake.  Ghrelin infusions into the VTA increase sucrose reward 
seeking, but injection into the NAC does not, suggesting the VTA is a locus for food 
motivation and reinforcing the notion that ghrelin acts on feeding through multiple pathways 
(Figlewicz and Sipols, 2010, Dickson et al., 2011, Skibicka and Dickson, 2011, Skibicka et 
al., 2011a). 
ICV infusion at least 1 nMol ghrelin causes animals to increase their food intake 
(Nakazato et al., 2001).  ICV administered ghrelin also results in an increased preference for 
high fat foods which leads to an increase in fat consumption (Shimbara et al., 2004).  Chronic 
ICV administration of ghrelin leads to weight gain and adiposity (Wren et al., 2001b).  ICV 
administration of ghrelin has also been known to cause increases in corticosterone levels and 
elevated body temperature (Jaszberenyi et al., 2006).  Infusion of 1 nMol ghrelin directly into 
the third ventricle results in increases in food seeking behaviors as well (Davidson et al., 
2005).  Intra-third ventricular infusion of ghrelin increases food intake to a larger degree in 
already fat rats as opposed to lean rats and fat rats had significantly higher GHS-R mRNA 
present in the hypothalamus (Brown et al., 2007).  When infused into the lateral ventricle or 
fourth ventricle, ghrelin stimulates food intake and increases expression of NPY mRNA 
(Kinzig et al., 2006, Spinedi et al., 2006) which suggests that ghrelin might act via NPY.        
ICV infusion of 1.5 nMol ghrelin also results in increased memory retention and 
induction of anxiety evidenced by increases in freezing in an open field and reduction in the 
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number of entries into the open arms of an elevated plus maze (Carlini et al., 2002).  Ghrelin 
promotes synapse formation in the hippocampus, which benefits spatial learning and memory 
and administration of ghrelin reverses the decreases in synapse density and impairments in 
memory observed following the ablation of the ghrelin gene (Diano et al., 2006).  Infusion of 
0.3 nMol and 3 nMol ghrelin directly into the hippocampus has been shown to improve 
memory consolidation (Carlini et al., 2010).  These observations suggest that ghrelin may be 
useful in improving memory in elderly individuals.  There is a possibility that ghrelin 
signaling may play a role in memory for food location, in behaviors such as foraging, for 
example. 
Ghrelin can alter the function of multiple systems and multiple neurochemical 
pathways.  ICV injection of ghrelin augments the release of norepinephrine and increases 
ACTH levels (Kawakami et al., 2008, Chuang and Zigman, 2010).  Although infusion of 
ghrelin activates the stress pathway, ghrelin levels do not rise following exposure to an 
external stressor (Zimmermann et al., 2007).  The ghrelin acylating enzyme, GOAT, has been 
implicated in glucose metabolism in that inhibition of GOAT prevents weight gain and 
lowers fat mass in mice on a high fat diet (Al Massadi et al., 2011).  Ghrelin activates DA 
neurons that are responsible for regulation of homeostasis (Abizaid et al., 2006a, Palmiter, 
2007, Abizaid and Horvath, 2008).  Exogenous administration of 10 nMol ghrelin has also 
been shown to have a neuroprotective effect in the substantia nigra pars compacta, where 
neuronal loss is involved with the development of Parkinson’s disease in mice (Andrews et 
al., 2009). 
There are also some studies that show that ghrelin produces its effects through 
pathways other than DA.  Some studies suggest ghrelin plays a role in the hypothalamic 
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pituitary system by activating the serotonin pathway, since previous research has shown 
ghrelin has the capacity to inhibit serotonin release in the hypothalamus (Brunetti et al., 
2002, Jaszberenyi et al., 2006).  Therefore, as ghrelin levels increase, the level of serotonin 
would then decline. It has been well established that serotonin inhibits food intake (Lam et 
al., 2010), so the implication of this observation is that ghrelin may increase food intake at 
least in part through inhibiting the release of serotonin.  Ghrelin administration (3 nMol) into 
the cerebral ventricles has been shown to induce changes in emotional responses, specifically 
increases in anxiety and depression thought to be caused by moderation of serotonin 
signaling (Hansson et al., 2011).  Another implication is that high levels of ghrelin may play 
a role in producing depression.  Depression is thought to, at least in part, be a result of 
decreases in synaptic availability of serotonin.  Since ghrelin inhibits the release of serotonin, 
higher levels of ghrelin might result in more severe cases of depression.  Therefore, it may be 
interesting to know if anti-depressants would work well in people suffering from depression 
that have high levels of ghrelin or whether ghrelin antagonists would be useful as anti-
depressant drugs. 
It is readily accepted that COC stimulates locomotion.  Acute systemic injection of 
ghrelin at a high enough dose to stimulate feeding (1 nMol) (Wren et al., 2001b) does not 
affect locomotion in rats by itself, but systemic ghrelin has been shown to augment the acute 
locomotor effects of COC in rats (Wellman et al., 2005).  Food restriction has also been 
shown to augment psychostimulant action and up-regulate circulating levels of rat ghrelin.  
Repeated administration of feeding-relevant doses of ghrelin (5, 10 nMol) over a period of 
ten days induces a cross sensitization to COC, which augments COC stimulated locomotor 
responses (Wellman et al., 2008b).  In other words, rats repeatedly exposed to ghrelin will 
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respond to their first exposure to COC with higher locomotor responses than do rats that 
were repeatedly exposed to vehicle.  This could be indicative of how ghrelin is known to 
reorganize inputs in the reward pathway particularly in the VTA, to result in neural activation 
(sensitization) (Abizaid et al., 2006b).  Injection of ghrelin directly into the VTA and the 
laterodorsal tegmental area result in an increase in locomotion and overflow of DA within the 
NAC (Jerlhag et al., 2007). 
As mentioned before, ghrelin levels increase during periods of food restriction.  Food 
restriction has been shown to augment psychostimulant induced CPP (Jerlhag et al., 2009).  
Administration of ghrelin augments food reward induced CPP in mice when using high fat 
foods (Perello et al., 2010).  In mice, i.p. injection of 3 nMol ghrelin was sufficient to 
produce CPP by itself (Jerlhag, 2008).  In rats, systemic administration of ghrelin prior to a 
CPP task augments the rewarding effects of COC, particularly in COC doses too low to 
induce a place preference by themselves (Davis et al., 2007).  Interestingly, at usual higher 
doses of COC, ghrelin causes the opposite effect.  What was found here was that the 
interaction of ghrelin and COC caused a leftward shift in the dose response curve for COC 
showing an augmentation of drug reward.  What this means is that this leftward shift in the 
inverted U dose response curve causes lower doses of COC act as though they were 
significantly higher doses.  Therefore, the highest dose tested appeared to be made aversive 
to the animals after ghrelin. 
The usual standard for investigating addiction is using a task in which the reward is 
self-administered which is studied in multiple stages (Carroll et al., 2004).  The first two 
stages are acquisition, which involves being conditioned to respond for a reward, and 
maintenance, which is demonstrated by continuing to respond for a reward in varying 
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conditions.  Lastly is extinction, where responding is discontinued following absence of 
reward for responding, and reinstatement, where there is restoration of the drug seeking 
behavior sometimes due to exposure to the previous conditioned stimulus.  Rats with higher 
serum ghrelin levels show higher incidence of reinstatement in COC self-administration after 
conditioned stimulus exposure compared to rats with lower ghrelin levels (Tessari et al., 
2007).  Self-administration of a reinforcer does not necessarily require exposure to drugs.  
ICSS tasks involve implanting electrodes into brain areas such as the medial forebrain bundle 
(MFB) and allowing responding to stimulate these areas with pleasurable pulses of electrical 
current (Olds and Milner, 1954).  Paradoxically, systemic administration of 10 nMol ghrelin 
produces a dose-dependent rightward shift in responding and an increase in response 
threshold for the MFB stimulation.  Systemic administration of COC produces the opposite 
effect, and ghrelin attenuates the COC shifts in responding when combining ghrelin and COC 
(Kniffin, unpublished data). 
As mentioned before, ICV or intra-VTA infusions of ghrelin have been shown to 
increase DA levels up to as much as 130% of baseline in the NAC (Jerlhag et al., 2006, 
Kawahara et al., 2009).  When ghrelin is administered peripherally, the change in DA 
overflow in the NAC is dependent on when the animal has last fed.  Consumption of food 
results in the same increases in DA overflow that are seen when ghrelin is administered 
centrally, but removing access to food decreases DA levels in the NAC after systemic ghrelin 
administration (Kawahara et al., 2009).  Ghrelin has also been shown to play a role in the 
regulation of arousal.  ICV administration of ghrelin promotes wakefulness as do injections 
into the medial preoptic-area and the PVN (Szentirmai et al., 2007).  Ghrelin has already 
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been shown to follow a circadian rhythm related to feeding times.  Administration of ghrelin 
in to the suprachiasmatic nucleus can advance the circadian phase (Yannielli et al., 2007).   
 It is well established that ghrelin stimulates food intake, but few studies have 
observed the interactions of ghrelin and food reinforcement.  Ghrelin administration has been 
shown to increase motivation to obtain food reward (Figlewicz and Sipols, 2010, Fulton, 
2010).  Infusion of ghrelin into the VTA causes rats to work harder to obtain food pellets 
than control rats (King et al., 2011).  Ghrelin administration into the VTA also increases 
motivation to obtain a sucrose reward (Skibicka et al., 2011a).  In addition to modulating 
food intake, systemic ghrelin has been shown to influence water consumption and centrally 
administered ghrelin inhibits water intake even while food was freely available during these 
water consumption tests (Mietlicki et al., 2009, Hashimoto and Ueta, 2011, Mietlicki and 
Daniels, 2011).  The suppressive impact of ghrelin on water intake is worthy of comment 
since this result is largely unexpected.  ICV infusion of ghrelin increases alcohol intake under 
free choice testing conditions (Jerlhag et al., 2009). 
 The other common approach to examining the role of ghrelin and reward is to 
inactivate ghrelin signaling.  This can be accomplished in many ways, the first of which is 
through pharmacological antagonism of GHS-Rs.  Before antagonists for the GHS-R were 
discovered, inverse agonists were used and were found to decrease the signaling of the GHS-
Rs (Mietlicki and Daniels, 2011).  Inverse agonists have negative efficacy and binding to 
receptors results in a response that is the opposite of what is produced by an agonist.  Inverse 
agonists have not been explored in much detail due to the arrival of a mixed agonist or mixed 
antagonist, BIM-28163, a ghrelin analog that acts as an antagonist of the GHS-Rs.  BIM-
28163 blocks ghrelin induced growth hormone secretion, but it mimics ghrelin in its capacity 
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Figure 3.  Structure of JMV 2959. 
to stimulate food intake and increase weight gain (Halem et al., 2004, Moulin et al., 2007b).  
BIM-28163 reduces the ghrelin-induced Fos expression in the medial ARC nucleus but up-
regulates Fos expression in the dorsal medial hypothalamus (Halem et al., 2005).  Intra-VTA 
infusion of BIM-28163 blocks the appetitive effects of ghrelin and attenuates food intake 
following food deprivation (Abizaid et al., 2006b).  Due to its varying effects on ghrelin 
signaling, BIM-28163 is not an ideal ghrelin antagonist.  After BIM-28163, came the 
antagonist used most often in the current literature which has been labeled JMV2959 
(Salome et al., 2009b). 
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 JMV2959 is a derivative of the triazole structure (Moulin et al., 2013) that (see Figure 
3) shows low nanomolar affinity for GHS-Rs and is not a mixed agonist like BIM-28163 
(Salome et al., 2009b, Wellman et al., 2012).  ICV infusion of JMV2959 suppressed ghrelin 
induced food intake and blocks the increased food intake following periods of food 
deprivation (Bell et al., 1997, Wellman et al., 2012).  Central administration of JMV2959 
suppresses ghrelin induced increases in body weight and fat mass, and blocks the ghrelin 
induced decreases in energy use (Salome et al., 2009b).  
 Pharmacological antagonism of GHS-Rs has been shown to alter ghrelin signaling, 
and what is of interest is the interaction between ghrelin and reward.  ICV or intra-tegmental 
ghrelin administration increases alcohol intake in a free choice test in mice, which is blocked 
with central or peripheral administration of JMV2959 (Jerlhag et al., 2009).  These results 
may represent a food intake effect or a reward effect.  JMV2959 also ablates CPP, DA 
release in the NAC, and locomotion increases following alcohol intake in mice (Jerlhag et al., 
2009).  Thus, ghrelin appears to alter ethanol reward, not simply ethanol’s effect on feeding.  
Further, other drugs of abuse such as COC and amphetamine cause increases in accumbal 
DA release and increases in locomotion which can be blocked with JMV2959 (Jerlhag et al., 
2010).  Administration of JMV2959 peripherally blunts the ability of nicotine (NIC) to 
increase locomotion and DA release in the accumbens (Jerlhag and Engel, 2011). 
 One way of examining the effects of ghrelin that was touched upon earlier is to look 
at drug sensitization.  It is well established that repeated administration of drugs of abuse can 
create sensitization such that each successive exposure to the drug results in an increased 
effect, compared to the previous one.  It was mentioned earlier that repeated administration 
of ghrelin produces a cross sensitization to drugs of abuse, particularly COC (Wellman et al., 
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2008b).  This suggests that GHS-R activity is required for the induction of locomotor 
sensitization to COC.  Similar to COC, NIC has the capacity to induce CPP and repeated 
administration of NIC induces locomotor sensitization.  
Another way of examining the role of ghrelin in drug abuse via inactivation of ghrelin 
signaling is to genetically ablate the GHS-R or ghrelin product.  One of the first studies to 
look at ghrelin knockout animals did so in mice and they were unable to find a difference 
between ghrelin knockout mice and wild type mice in regards to ghrelin stimulated feeding 
(Sun et al., 2003).  However, ghrelin-knockout and GHS-R-knockout mice on restricted 
feeding schedules show reduced feeding compared to wild type controls (Abizaid et al., 
2006b).  Ghrelin-knockout and GHS-R-knockout mice also exhibit reduced blood glucose 
levels and respiration was mildly inhibited in the ghrelin-knockout mice (Sun et al., 2008). 
 As mentioned before, ghrelin seems to play a role in behaviors associated with 
anticipation of feeding.  Animals sustaining genetic ablation of the GHS-R show attenuated 
meal anticipatory locomotion and attenuated Fos expression in the hypothalamus compared 
to wild type littermates (Blum et al., 2009).  GHS-R (-/-) mice show attenuated food 
anticipatory stimulated locomotion (LeSauter et al., 2009).  Knockout of ghrelin in mice also 
decreases arousal and increases sleeping during the periods of light as well as decreases in 
sleep during periods of the dark (Szentirmai et al., 2009).  GHS-R knockout mice also fail to 
develop a CPP to high fat diets as seen in wild type mice (Perello et al., 2010). 
What is of interest here is the effect that genetic ablation of ghrelin or GHS-Rs has on 
the interaction of ghrelin and drug reward.  As mentioned before, food restriction augments 
the behavioral and reinforcing effects of psychomotor stimulants such as COC possibly via 
increases in ghrelin levels.  Under food restriction, GHS-R knockout mice do not 
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significantly increase anticipatory locomotor activity relative to wild types, but 
administration of COC at doses of at least 1.25 mg/kg is sufficient to increase locomotion in 
these ghrelin knock outs to a level equivalent to that seen in wild types (Clifford et al., 2011).  
Ghrelin knockout mice display a decrease in COC-induced stimulation of locomotion as well 
as ablation of DA changes in the striatum seen in wild type mice (Abizaid et al., 2011).  The 
capacity of alcohol to increase DA release is blocked in ghrelin knockout mice and the 
alcohol induced locomotor increases are attenuated compared to wild type controls (Jerlhag 
et al., 2011). 
GHS-R(-/-) rats have been developed in Fawn Hooded Hypertensive (FHH) rats.  The 
FHH-Ghsrm1/Mcwi [GHS-R (-/-)] strain was generated by the PhysGen Program in Genomic 
Applications by N-ethyl-N-nitrosourea (ENU) mutagenesis of Fawn Hooded Hypertensive 
(FHH) strain animals. Briefly, ENU-treated males were backcrossed and offspring were 
screened using a Targeting Induced Local Lesions in Genomes (TILLing) approach (Till et 
al., 2007). GHS-R-specific primers GHS-R_F: 5’- GTTTGTCAGTAGGCATGCAG -3’ and 
GHS-R_R: 5’- GAAAGGCCATGTCTTAAGTTG -3’ were used to screen for mutations in 
exon 2 of GHS-R (GenBank accession number NM_032075). The GHS-Rm1/Mcwi mutation 
was evident as a C>T transition of base pair of nucleotide 1027 of this sequence by Sanger 
sequencing, creating glutamine (CAG) to stop (TAG) codon change. This mutant animal was 
backcrossed and then intercrossed for more than 15 generations. Sanger sequencing was used 
to confirm the animals are homozygous. 
 While genetic ablation of GHS-Rs and pharmacological antagonism of GHS-Rs are 
the most common ways to examine inactivation of ghrelin signaling, there are some 
additional methods that need further exploration.  As discussed earlier, there are GHS-Rs in 
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the vagus nerve and vagotomy is one approach to investigate ghrelin signal inactivation.  
Vagotomy does not have an effect on baseline levels of ghrelin, but it does prevent the rise in 
ghrelin seen after periods of food deprivation (Williams et al., 2003).  The effect ghrelin has 
on food intake can also be blocked by immunosuppression.  Acyl-ghrelin specific antibodies 
bind to acyl-ghrelin and inhibit calcium signals and ghrelin induced feeding increases in mice 
(Lu et al., 2009).  Interfering with RNA to reduce ghrelin gene expression is another way 
ghrelin inactivation can be studied.  This RNA interference lowers body weight and reduces 
blood ghrelin levels as much as 500 pg/ml (down from 2200 pg/ml) without having an 
impact on feeding (Shrestha et al., 2009).  Polymorphisms of the genes that contol production 
of either ghrelin or of ghrelin receptors might impair ghrelin function and may provide clues 
as to the functions of the ghrelin systems.  Research shows that a polymorphism of the GHS-
R has been linked to high alcohol consumption in human females and that high alcohol 
consumption can be suppressed with antagonism of GHS-Rs (Landgren et al., 2012).  No 
research to date has linked such polymorphisms to either cocaine or nicotine addiction in 
humans. 
Ghrelin seems to be involved in a number of important processes and being able to 
alter ghrelin signaling would be helpful in treating diseases and disorders associated with 
these functions, one example would be ghrelin vaccination (Zigman and Elmquist, 2006, 
Leite-Moreira and Soares, 2007).  One vaccine study was done showing that rats 
administered a ghrelin vaccine slowed their weight gain and gained less body fat (Zorrilla et 
al., 2006).  A GHS-R vaccine could potentially be used as well and administered ICV.  Due 
to ghrelin’s diverse effects, ghrelin signaling could be a useful avenue of therapy for obesity, 
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anorexia, gastric ulcers, and perhaps reproduction problems (Leite-Moreira and Soares, 
2007). 
In addition to ghrelin playing a role in drug abuse, drugs of abuse can play a role in 
altering ghrelin signaling.   Ecstasy or 3,4-methylenedioxymethamphetamine (MDMA) 
causes acute increases in ghrelin levels which could explain changes in appetite (Kobeissy et 
al., 2008).  It has been shown previously that increases in ghrelin activity causes increases in 
VTA activity, and the VTA has also been implicated in sexual reward (van Furth and van 
Ree, 1996).  Increases in ghrelin levels in the VTA cause an increase in sexual reward.  This 
opens up the possibility that ghrelin may play a role in the reinforcing properties of sexual 
behavior.  Since MDMA causes an increase in ghrelin levels, it may exert at least part of its 
increase in sexual reward and sexual motivating effects through the ghrelin-VTA pathway.  
Ghrelin has also been implicated in sexual development, and ghrelin seems to play a role in 
the regulation of puberty (Repaci et al., 2011).  
Based on the aforementioned literature, a logical step forward would be to examine 
the effects of modulation of ghrelin signal activity regarding drugs of abuse.  The focus of 
the present experiments was to employ two distinct strategies to examine the role of GHS-Rs 
in drug-induced locomotor sensitization as well as shifts in ICSS response rates induced by 
COC or by NIC.  The first strategy involved the use of JMV 2959 to antagonize GHS-Rs, 
while the second strategy was the genetic ablation of GHS-Rs in a genetic knockout rat.
  
 
* Part of this chapter is reprinted with permission from “Lobeline attenuates progressive ratio breakpoint scores 
for intracranial self-stimulation in rats” Wellman PJ, Elliott AE, Barbee S, Hollas CN, Clifford PS, Nation JR, 
2008. Physiology & Behavior 93:952-957, Copyright 2007 by Elsevier. 
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CHAPTER II 
GENERAL METHODS* 
 
Subjects 
Male Sprague-Dawley rats (Harlan Houston) and male Fawn Hooded Hypertensive 
(FHH) rats were used for the experiments.  Age-matched parental FHH/EurMcwi strain 
males were provided as controls in our experiments.  WT and GHS-R(-/-) rats were held in 
quarantine for 30 days after arrival at TAMU.  All rats were acclimated to the colony for a 
minimum of 7 days before the start of any experiment.  All rats received food and water ad 
libitum and were housed on a 12:00 hour light/dark cycle with the lights on at 8:00am and off 
at 8:00pm. All procedures were conducted in accordance with the National Institutes of 
Health (NIH) Guide for the Care and Use of Laboratory Animals after receiving the approval 
of Texas A&M University’s Institutional Animal Care and Use Committee.  
 
Housing 
 Both the Sprague-Dawley and Fawn Hooded Hypertensive rats were single housed in 
standard polycarbonate cages with continuous access to food and water except as noted 
below.  The colony room temperature was maintained at 21 + 1 o C while the humidity was 
maintained at 60-70%. 
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Drugs 
 COC solutions were prepared by dissolving COC hydrochloride (a gift provided by 
Dr. Kevin Gormley of the Basic Research Division of NIDA) into 0.9% saline at 
concentrations of 10 mg/ml.  COC dose was calculated as the salt.  COC doses were chosen 
based on earlier studies involving locomotor sensitization (Miller et al., 1999).  NIC was 
prepared by dissolving NIC hydrogen tartrate salt (HT: Sigma, St. Louis, MO, USA) into 
0.9% saline at a concentration of 0.25 or 0.4 mg/ml, calculated as the free base.  The pH of 
the NIC solution was adjusted to ~ 7.0 using sodium hydroxide.  NIC doses were chosen 
based on other studies involving NIC induced locomotion (Bevins and Palmatier, 2003, 
Santos et al., 2009, Zago et al., 2012).  The JMV 2959 hydrogen chloride was dissolved into 
0.9% saline at a concentration of 3.0 and 6.0 mg/ml calculated as the salt and was 
administered in a volume of 1.0 ml/kg.  The JMV 2959 was a kind gift from Jean-Alain 
Fehrentz of the Institut des Biomolécules Max Mousseron, Faculté de Pharmacie, 34093 
Montpellier Cedex 5, France.  JMV 2959 doses were chosen based on locomotor activity 
studies done by Jerlhag’s group (Jerlhag and Engel, 2011).  Sodium pentobarbital was 
prepared by diluting a stock solution (Beuthanasia-D) with 0.9% saline to a final 
concentration of 100 mg/ml which was administered i.p. at a volume of 1 mg/ml.  Ketamine 
solutions were prepared by mixing 80% ketamine (Ketaset: 80 mg/kg, Bioniche Pharma 
USA, Lake Forest, IL) and 20% xylazine (20 mg/kg). 
 
Surgical Procedures 
 For the ICSS experiments (5 and 6), surgical implantation of stimulating electrodes 
was required.  Surgical procedures follow those outlined in Wellman et al., 2008 (Wellman et 
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al., 2008a).  Prior to surgery, each rat was injected (i.p.) with 0.4 mg/kg atropine sulfate (to 
minimize bronchial secretions), and then anesthetized using an injection (i.p.) of ketamine 
(Ketaset: 80 mg/kg) and xylazine (20 mg/kg). Each rat was mounted in a stereotaxic frame 
and the scalp incised using sterile technique. A 2% lidocaine jelly was applied to the incised 
edges of the scalp as pain relief to prevent scratching. The periosteum was mechanically 
retracted and skull bleeding was terminated using a styptic gel (Kwik-Stop, Gimborn Pet, 
Atlanta, GA). A bipolar stimulating electrode with 0.125-mm wire diameter (Plastics One, 
Roanoke, VA; No. 303/3) was implanted into the MFB at the level of the lateral 
hypothalamus. The incisor bar was set at −2.7 mm, and coordinates were 3.2 mm posterior to 
bregma, 1.7 mm lateral to the sagittal suture, and 8.3 mm ventral to the skull surface. 
Electrodes were affixed to the skull with three skull screws and dental acrylic (Lang Dental; 
Wheeling, IL). The lateral edges of the scalp incision were coated with a 0.1% gentamicin 
sulfate ointment (E. Fougera; Melville, NY) and the ends of the incision were closed using 
cyanoacrylate. Following surgery, each rat was injected (i.m.) with ampicillin (300,000 
units). Butorphanol (0.05 mg/kg, SC: Dolorex) was used to alleviate post-surgical 
discomfort.  A 7-day recovery period followed surgery, during which the rats were handled 
and weighed daily and had continuous access to water and food pellets in the home cage. 
 
Histology Procedures 
At the conclusion of the ICSS experiments, each rat was overdosed with sodium 
pentobarbital (100 mg/kg, i.p.), and perfused through the heart with 0.9% phosphate buffered 
saline followed by 10% formalin. Further fixation in 10% formalin/30% sucrose proceeded 
for at least 72 h prior to sectioning each brain. Alternate 80 um frozen sections were cover-
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slipped for permanent storage. Coronal scans were compared to standard atlas plates 
(Paxinos and Watson, 2004) to verify electrode placements. 
 
Apparatus 
 The assessment of locomotion was made in a set of 8 automated optical beam activity 
monitors (Model RXYZCM-16; Accuscan Instruments, Columbus, OH, USA).  Each 
monitor was housed within a 40 X 40 X 30.5 cm acrylic cage.  Activity monitors and cages 
were located in a sound-proof room with a 40 dB [SPL] white noise generator operating 
continuously. A multiplexor-analyzer monitored beam breaks from the optical beam activity 
monitors and tracked the simultaneous interruption of beams. The multiplexor-analyzer 
updated the animal's position in the acrylic cage every 10 ms using a 100% real-time 
conversion system. Computerized integration of the data obtained from the monitor afforded 
the recording of general activity using total distance (in cm) as the primary dependent 
measure. 
 For the ICSS experiments, the test chamber (Cambden Instruments) was constructed 
of Plexiglas and stainless steel with dimensions of 28x22x22 cm.  Two levers were mounted 
on opposite sides of one wall 7 mm above the floor.  Depression of the right lever was 
without consequence, while depression of the left lever resulted in the delivery of a 500-ms 
train of monophasic rectangular pulses with 1-ms pulse duration delivered from a Grass S88 
stimulator (Grass Instruments, Quincy, MA) and a constant current stimulator (Model DS3; 
Digitimer, Hertfordshire, England) to the brain via a commutator and a flexible cable 
(Plastics One).  All stimulation parameters were monitored on an oscilloscope (Model 
645280; Jameco Electronics, Belmont, CA).
  
 
* Part of this chapter is reprinted with permission from “Attenuation of cocaine-induced locomotor sensitization 
in rats sustaining genetic or pharmacologic antagonism of ghrelin receptors” Clifford, PS, Rodriguez, J, Schul, 
D, Hughes, S, Kniffin, T, Hart, N, Eitan, S, Brunel, L, Fehrentz, JA, Martinez, J, Wellman, PJ, 2011. Addiction 
Biology 17(6):956-63, Copyright 2011 by Wiley. 
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CHAPTER III 
EXPERIMENT 1:  EFFECT OF JMV 2959 ON COCAINE-INDUCED LOCOMOTOR 
SENSITIZATION* 
 
Background 
The literature suggests that ghrelin and GHS-Rs modulate reinforcement to addictive 
drugs that activate brain DA circuits (Jerlhag et al., 2006, Abizaid, 2009, Perello et al., 2010, 
Dickson et al., 2011).  Consistent with this are studies mentioned previously that show 
systemic administration of ghrelin enhances COC-induced hyper locomotion (Wellman et al., 
2005) and chronic daily injection of ghrelin in rats enhances locomotor sensitization to an 
acute injection of COC (Wellman et al., 2008b).  Also, systemic and central administration of 
ghrelin can induce CPP (Jerlhag, 2008, Jerlhag et al., 2010), as well as enhance CPP induced 
by COC and by food (Davis et al., 2007, Egecioglu et al., 2010, Perello et al., 2010).  
Another way to assess the role of ghrelin in addictive drug effects involves inactivation of 
GHS-Rs. 
Pharmacological antagonists of GHS-Rs were developed, at first because ghrelin is 
known to induce feeding, with the idea that inactivation of GHS-Rs could be used in the 
treatment of obesity.  One of these antagonists is JMV 2959 which binds to GHS-Rs with 
low nanomolar affinity (Salome et al., 2009a).  As would be expected of a GHS-R 
antagonist, s.c. administration of JMV 2959 dose-dependently blocked the feeding response 
induced by a synthetic ghrelin agonist hexarelin (Moulin et al., 2007a).  JMV 2959 represents 
28 
 
an important tool for the role of GHS-Rs in drug abuse.  Pharmacological inactivation of 
GHS-Rs by JMV 2959 has been shown to attenuate or to ablate the acute locomotor and CPP 
properties of amphetamine, COC, ethanol, and most recently that of NIC (Jerlhag et al., 
2009, Jerlhag et al., 2010, Jerlhag and Engel, 2011, Jerlhag et al., 2011).  This experiment 
considered the impact of JMV 2959 on the development of locomotor sensitization induced 
by daily administration of COC in rats.  Sensitization involves repeated exposures to a drug 
on a continuous basis.  Repeated exposure produces an increase in the reaction to the drug on 
each of the successive days.  An animal exposed to a single dose of COC will display an 
increase in locomotor response and the locomotor increase will be higher on day two after 
COC than they were on day one and so on.  Locomotor sensitization is interpreted to reflect 
dynamic changes in the brain dopamine systems and these changes are assumed to be 
predictive of the ability of a drug to induce addiction.  Put another way, locomotion is not 
addiction, but drugs that produce sensitization of locomotion are known to be addictive 
(Wise and Leeb, 1993). Drugs that have the capacity to block development of locomotor 
sensitization would presumably be useful for the prevention of COC addiction.  Since COC 
acts in the NAC (Sellings et al., 2006), which contains GHS-Rs (Dickson et al., 2011), then 
antagonism of GHS-Rs would be expected to diminish the locomotor effects of COC.   If 
antagonism of GHS-Rs diminishes the reinforcing effects of COC, ghrelin antagonists could 
prove useful in treatment of COC addiction. 
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Experiment Procedures 
Subjects  
The subjects of this experiment were 24 adult male Sprague-Dawley rats obtained 
from Harlan (Houston, Texas) weighing 250-275 g at the start of the experiment. 
 
 
JMV2959 Coc 
Locomotion 
Days: -5 to -4 Days: -3 to 0 Days: 1 - 7 
Adaptation Saline 
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Saline 
Cocaine 
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Figure 4.  Behavioral Analysis  of Experiment 1:  Effect of JMV 2959 on COC-
induced locomotor sensitization. 
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Behavioral Analysis 
 On two consecutive days, the rats were adapted to the locomotion chambers for 60 
min per day.  This adaptation period is essential because it serves to reduce baseline 
locomotion from the increased level seen when a rat encounters a novel environment (Miller 
et al., 1999).  Over the next three days, the rats were injected with 0.9% saline (1 ml/kg) 5 
min before being placed into the activity chamber.  The rats were placed into the locomotion 
chambers for 15 min to habituate to the novel environment, removed and then injected with 
0.9% saline and then placed back into the chambers for 45 min. During the 14 day COC 
exposure period, half of the rats in each injection condition were treated with either vehicle 
or 6 mg/kg JMV 2959 at 5 min before being placed into the locomotion chambers.  After the 
15 min baseline period, the rats were injected with either saline or 10 mg/kg COC hydrogen 
chloride and placed back into the locomotion chamber for 45 min.  Therefore, there were 20 
min between exposure to JMV 2959 and COC (see Figure 4).  The reason for this is that it is 
known that JMV 2959 is rapidly absorbed and active in the brain during this lag period 
(Moulin et al., 2013).  This pretreatment-treatment combination formed four test groups: 
vehicle-vehicle (n=5), vehicle-COC (n=5), JMV 2959-vehicle (n=7), and JMV 2959-COC 
(n=7).  
 
Data Analysis 
 The overall design of the study was a split-plot (mixed) factorial design consisting of 
between-group factors of pretreatment status (vehicle versus 6 mg/kg JMV 2959) and COC 
exposure (vehicle versus 10 mg/kg COC) and a within-group factor of day.   Because the 
treatment means and variances were proportional, the total distance traveled scores were 
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subjected to a log transformation (Kirk, 1982).  Statistical significance was deemed to be p < 
0.05 and the Bonferroni procedure was used to examine mean group differences. 
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Figure 5. Impact of 6 mg/kg JMV 2959 on COC locomotor sensitization.  Mean group 
total changes in total distance traveled scores (cm/45 min).  On day 0, the rats were 
injected with vehicle at 10 min prior to the 15 min baseline period and then again with 
vehicle just prior to the 45 min test period. During days 1-7, the rats were injected with 
either vehicle (VEH) or 6 mg/kg JMV 2959 (JMV) at 10 min prior to the 15 min baseline 
period and then injected with either vehicle or 10 mg/kg COC (COC) just prior to the 45 
min test period on days 1-7.  The star (*) indicates a significant (p < 0.05) difference 
between the respective Veh and Coc groups.  The lines above each symbol represent 
the S.E.M.  Vehicle-vehicle (n=5), vehicle-COC (n=5), JMV 2959-vehicle (n=7), and JMV 
2959-COC (n=7) 
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Results 
On the last day of the baseline procedure (Day 0 in Figure 5), there were no 
significant differences in 15 min locomotor scores (p > 0.320).  Analyses of the 15 min 
scores, data not depicted, after administration of JMV 2959 (but before COC or vehicle) 
revealed a significant suppressive effect of JMV 2959 on baseline locomotion scores (F(1,20) 
= 110.3, P < 0.0001) as well as a significant interaction between the factors of day and JMV 
2959 treatment (F(7,140) = 12.9, P < 0.0001).  Analyses of the 45 min locomotor data on day 
0 revealed no significant between group differences as a function of JMV 2959 treatment (p 
= 0.334), although there was a trend for the JMV-vehicle group to exhibit lower locomotion 
scores on Day 0 relative to the other groups.  Additionally, the baseline scores revealed a 
significant inhibitory effect of JMV 2959 on locomotion during the first 15 min after 
administration.  Accordingly, separate ANOVAs of the data were computed for the vehicle 
treatment and COC treatment conditions to compare the effect of JMV on locomotion.  
Considering the impact of JMV 2959 versus vehicle in rats treated with vehicle, ANOVA 
revealed no significant effect of JMV 2959 dose (p = 0.058), no effect of days (p > 0.307) 
and no interaction between JMV 2959 dose and days (p = 0.9503).  The near significant trend 
for the JMV 2959 factor was attributed to the initial differences in these groups prior to the 
start of the JMV 2959 administration.  A second analysis considered the impact of JMV 2959 
in rats treated with 10 mg/kg COC.  These analyses revealed no overall effect of JMV 2959 
dose (p = 0.497), but revealed a significant effect of day (F(6,72) = 12.5, p < 0.002), as well 
as a significant interaction between JMV 2959 treatment and day (F(6,72) = 4.228, p < 0.04).  
The latter interaction reflected the fact that the JMV 2959-COC and vehicle-COC groups 
exhibited similar increases in locomotion during days 1-4, but the groups diverged during 
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days 5-7.  In contrast, no such divergence was evident in the vehicle-vehicle and JMV 2959-
vehicle groups.  Indeed, the separation of the vehicle-vehicle and JMV 2959-vehicle groups 
were similar throughout the 7 days whereas the separation between the JMV 2959-COC and 
vehicle-COC groups was not evident until day 5 of the study. 
 
Discussion 
 There is a growing body of evidence suggesting that modulation of CNS GHR 
activity can alter DA neuron circuits in rats and mice and in turn alter brain reinforcement 
function.  These studies include the localization of GHS-Rs on DA neurons within the VTA 
(Guan et al., 1997, Naleid et al., 2005, Abizaid et al., 2006b, Diano et al., 2006, Abizaid, 
2009) and the demonstration that systemic and intra-VTA administration of GHR can 
modulate DA release within the NAC (Jerlhag et al., 2006, Jerlhag et al., 2007, Quarta et al., 
2009).  Consistent with these studies, our laboratory has examined changes in the behavioral 
actions of COC in rats given supplemental doses of GHR.  As expected, GHR administration 
facilitates acute COC hyper locomotion in rats (Wellman et al., 2005),  induces a degree of 
behavioral sensitization to COC (Wellman et al., 2008b) and can facilitate CPP induced by 
low doses of COC (Davis et al., 2007).   
 The present study considered the development of locomotor sensitization induced by 
repeated administration of 10 mg/kg COC in rats for which GHR receptors were subject to 
pharmacological inactivation.  With regard to GHS-R activity and baseline locomotion, the 
present results in which inactivation of GHS-Rs diminished baseline locomotion (see Figure 
5) are consistent with other studies in which functional GHS-R activity is key to locomotion 
(Abizaid et al., 2006b, Jerlhag et al., 2006, Blum et al., 2009).  The effect of JMV 2959 on 
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locomotion scores was significant for the first 15 min after treatment, but not for the next 45 
min.  The present experiment indicates pharmacological inactivation of GHS-Rs results in 
the attenuation of the development of COC locomotor sensitization.  This effect was not 
evident during the initial hyperlocomotor effect of COC, but rather became evident after 
repeated COC exposures while the animals were in the process of developing locomotor 
sensitization.
  
 
* Part of this chapter is reprinted with permission from “Pharmacologic antagonism of ghrelin receptors 
attenuates development of nicotine induced locomotor sensitization in rats” Wellman, PJ, Clifford, PS, 
Rodriguez, J, Hughes, S, Eitan, S, Brunel, L, Fehrentz, JA, Martinez, J, 2011. Regulatory Peptides, 172(1-3):77-
80, Copyright 2011 by Elsevier. 
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CHAPTER IV 
EXPERIMENT 2:  EFFECT OF JMV 2959 ON NICOTINE-INDUCED LOCOMOTOR 
SENSITIZATION* 
 
Background 
The idea behind this experiment follows the same reasoning as in the first experiment, 
except NIC was used in place of COC.  Previous studies from Jerlhag and Engel suggest that 
acute antagonism of GHS-Rs blocks the acute locomotor effects of NIC in mice (Jerlhag and 
Engel, 2011).  Similar to COC, NIC has the capacity to induce CPP and repeated 
administration of NIC induces locomotor sensitization (Smith et al., 2010).  Also, 
pharmacological antagonists of GHS-Rs might be useful in assisting in the cessation of 
smoking if it diminishes the rewarding properties of NIC, since it has already been shown 
that GHS-Rs antagonists have the capacity to decrease food intake.  Central administration of 
JMV2959 suppresses ghrelin induced increases in body weight and fat mass, and blocks the 
ghrelin induced decreases in energy use (Salome et al., 2009b).  This experiment considered 
the impact of JMV 2959 on the development of locomotor sensitization induced by daily 
administration of NIC in rats.  Since NIC acts in the VTA where GHS-Rs are present, then 
antagonism of GHS-Rs would be expected to diminish the locomotor effects of NIC.  If 
antagonism of GHS-Rs diminishes the reinforcing effects of NIC, ghrelin antagonists could 
prove useful in treatment of NIC addiction. 
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Experimental Procedures 
Subjects 
 The subjects of this experiment were 40 adult male Sprague-Dawley rats obtained 
from Harlan (Houston, Texas, USA) weighing 250-275 g at the start of the experiment.   
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Figure 6. Behavioral Analysis of Experiment 2:  Effect of JMV 2959 on 
NIC-induced locomotor sensitization. 
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Behavioral Analysis 
 On two consecutive days, the rats adapted to the locomotion chambers for 60 min per 
day. On the next three days, the rats were injected (i.p.) with 0.9% saline (1 ml/kg) 5 min 
before being placed into the activity chamber.  The last day of the vehicle injection trials 
served as day 0 for baseline.  The rats were placed into the locomotion chambers for 15 min, 
removed and then injected with 0.9% saline and then placed back into the chambers for an 
additional 45 min. During the 7 day NIC exposure period, a third of the rats in each NIC 
injection condition were treated (i.p.) with vehicle (0), 3 or 6 mg/kg JMV 2959 at 5 min 
before being placed into the locomotion chambers.  After the 15 min baseline period, the rats 
were injected (s.c.) with either saline or 0.4 mg/kg NIC HT then placed back into the 
locomotion chamber for 45 min (see Figure 6).  This pretreatment-treatment combination 
formed six test groups: vehicle-vehicle (n=6), vehicle-NIC (n=6), 3 mg/kg JMV 2959-vehicle 
(n=8), 3 mg/kg JMV 2959-NIC (n=8), 6 mg/kg JMV 2959-vehicle (n=6), and 6 mg/kg JMV 
2959-NIC (n=6). 
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Results 
On the last day of the baseline procedure (Day 0 in panels A and B of Figure 7), there 
were no significant effects of NIC dose (F(1,34) = 0.17, P < 0.685) or of JMV 2959 dose 
(F(1,34) = 0.001, P < 0.999), and there was no significant interaction among these factors 
(F(2,34) = 0.24, P < 0.788) on baseline 45 min locomotion scores.  A split-plot ANOVA of 
Figure 7.  Impact of 3 and 6 mg/kg JMV 2959 on NIC locomotor sensitization.  
Mean group total changes in total distance traveled scores (cm/45 min).  On day 0, the 
rats were injected with Veh at -5 min prior to the 15 min baseline period and then 
again with Veh just prior to the 45 min test period. During days 1-7, the rats were 
injected with either Veh, 3 mg/kg JMV 2959 (JMV 3: panel A) or 6 mg/kg JMV 2959 
(JMV 6: panel B) at -5 min prior to the 15 min baseline period and then injected with 
either vehicle or 0.4 mg/kg NIC (Nic) just prior to the 45 min test period on days 1-7.  
The lines above and below each symbol represent the SEM.  The star (*) indicates a 
significant (p < 0.05) difference between the respective Veh and Nic groups.   
Vehicle-vehicle (n=6), vehicle-NIC (n=6), 3 mg/kg JMV 2959-vehicle (n=8), 3 mg/kg 
JMV 2959-NIC (n=8), 6 mg/kg JMV 2959-vehicle (n=6), and 6 mg/kg JMV 2959-
NIC (n=6). 
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the changes in locomotion induced by 0, 3 or 6 mg/kg JMV 2959 across the treatment days in 
vehicle treated rats (data depicted in Panels A and B of Figure 7) revealed no significant 
effect of days (F(7,119) = 0.556, P < 0.790), or of JMV 2959 dose (F2,17) = 1.448, P < 
0.254), nor was there a significant interaction between days and JMV 2959 dose (F(14,119) = 
1.055, P < 0.405).  Although there was a trend for 6 mg/kg JMV 2959 to reduce locomotion 
on some days, these differences were not significant nor was there an effect of 3 mg/kg JMV 
2959 on locomotion in rats treated with vehicle. 
An overall split-plot ANOVA was computed to determine the impact of NIC (0 vs. 
0.4 mg/kg) and of JMV 2959 (0, 3 or 6 mg/kg) on locomotion across the 8 days of this 
experiment.  These analyses revealed a significant overall effect of day (F(1,34) = 40.33, p < 
0.0001) as well as interactions between NIC dose and day (F(1,34) = 48.24, p < 0.0001), 
JMV 2959 dose and day (F(2,34) = 9.89, p < 0.0001), and a triple interaction between NIC 
dose, JMV 2959 dose and day (F(2,34) = 4.79, p < 0.015).   
Results with NIC and JMV 2959 are depicted in the three panels of Figure 7.  In panel 
A, administration of 0.4 mg/kg NIC in vehicle pretreated rats initially suppressed locomotion 
on treatment day 1 and over the next 6 days, this treatment resulted in significant 
sensitization of locomotion to levels nearly three times that noted in vehicle treated rats.  Post 
hoc contrasts revealed significant differences (p < 0.05) between the Veh-Veh group and the 
Veh-Nic group on days 5, 6, and 7.  In panels A and B, rats pretreated with either 3 or 6 
mg/kg JMV 2959 and then treated with NIC showed an initial (but non-significant) 
suppression of locomotion lasting 1-2 days, but failed to exhibit a subsequent significant 
enhancement of locomotion as was induced by 0.4 mg/kg NIC in vehicle pretreated rats.  In 
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panels A and B, no contrasts between Veh and Nic treatments were significant for any dose 
of JMV 2959. 
Discussion 
 The present study considered the development of locomotor sensitization induced by 
repeated administration of 0.4 mg/kg NIC in rats for which GHR receptors were antagonized 
by pretreatment with the GHS-R antagonist JMV 2959 (Moulin et al., 2007a, Salome et al., 
2009b).  Rats that were pre-treated with JMV 2959 showed significant attenuation of the 
development of hyperlocomotion to daily injections of 0.4 mg/kg NIC.  However, when JMV 
2959 was administered by itself, the 6 mg/kg dose slightly reduced locomotion but the 3 
mg/kg dose did not (see Figure 7).  This outcome parallels a recent study done in Long-
Evans rats showing behavior disruptions when these rats were given 6 mg/kg JMV 2959, but 
no behavioral disruptions were seen in rats given lower doses such as 1, 2 or 3 mg/kg JMV 
2959 (Landgren et al., 2012).  In the present study, both 3 and 6 mg/kg JMV 2959 produced 
similar attenuation of the development of NIC-induced hyper locomotion.  What this 
suggests is that the attenuation of locomotor sensitization to NIC is not wholly due to JMV 
2959 disrupting baseline locomotion in and of itself.  The blunted development of NIC 
locomotor sensitization reported herein is similar in direction (but not magnitude) to what is 
seen in experiment 1 in which the same 6 mg/kg of JMV 2959 was noted to attenuate the 
sensitization induced by daily injection of 10 mg/kg COC in rats (Clifford et al., in press). 
Taken together, these results strongly implicate functional GHS-R activity as required for the 
induction of locomotor sensitization by psychostimulants.  
Acute administration of JMV 2959 has been shown to reduce locomotion, block the 
induction of CPP and blunt the ability of NIC to increase locomotion and DA release in the 
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accumbens in mice (Jerlhag and Engel, 2011).  These effects are likely due to activation by 
NIC of nicotinic cholinergic afferents projecting to the VTA, which in turn activate DA 
overflow within the NAC (Jerlhag et al., 2006).  This study looks at chronic pharmacological 
inactivation of GHS-Rs and the ability of GHS-R antagonists to significantly diminish the 
locomotor sensitization induced by NIC in rats, the process of NIC sensitization is unknown. 
Since GHS-Rs are critically involved in the induction of eating (Tschop et al., 2000, 
Abizaid, 2009, Egecioglu et al., 2010), antagonism of GHS-Rs has been a key focus of 
appetite suppressant drug development.  Pharmacological antagonism of GHS-Rs can 
diminish baseline feeding and attenuate the rewarding action of food (Egecioglu et al., 2010, 
Perello et al., 2010).  This experiment shows that antagonism of GHS-R function and its 
ability to reduce the development of NIC sensitization may be useful in the treatment for NIC 
addiction.  Such an outcome may suggest that GHS-R drug antagonists may have multiple 
avenues for the treatment of NIC addiction.  The first way it can combat NIC addiction is by 
diminishing the rewarding action of NIC.  Another way to combat NIC addiction might be to 
prevent the weight gain often noted following cessation of smoking.   Oftentimes this weight 
gain is an important enough barrier to prevent people from quitting smoking (Pomerleau and 
Saules, 2007).  Additionally, a distinct haplotype of the GHS-R is associated with smoking 
risk in low-level female consumers of alcohol, though how it affects ghrelin signaling is yet 
unknown (Landgren et al., 2010).   
  In contrast to the impact of inhibition of GHR signaling on COC behavioral function, 
our earlier laboratory studies showed that administration of GHR facilitates COC-induced 
hyper locomotion and COC-induced CPP (Wellman et al., 2005, Davis et al., 2007, Wellman 
et al., 2008b).  Repeated administration of feeding-relevant doses of ghrelin (5, 10 nMol) 
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induces a cross sensitization to COC, which augments COC stimulated locomotor responses 
(Wellman et al., 2008b).  In other words, rats repeatedly exposed to ghrelin will respond to 
their first exposure to COC with higher locomotor responses than do rats that were exposed 
with vehicle.  This study needs to be replicated with regards to NIC.  This could be indicative 
of how ghrelin is known to reorganize inputs in the reward pathway particularly in the VTA 
to result in neural activation (sensitization) (Abizaid et al., 2006b).  This effect may also be 
related to an up-regulation of D1 receptors such that ghrelin can amplify DA signaling (Jiang 
et al., 2006).  Though, this is in opposition to our experiments showing that antagonism of 
GHS-Rs diminishes the development of sensitization to NIC and to COC.  A more general 
role for GHS-Rs in brain reinforcement is also indicated by recent studies in which 
pharmacological inactivation of GHS-Rs attenuates the CPP induced by ethanol (Jerlhag et 
al., 2009) and in which genetic ablation of GHS-Rs attenuates the CPP induced by ingestion 
of high-fat foods (Perello et al., 2010).  GHS-Rs also play a key role in the consumption of 
sweet tasting food and drink in rats and humans (Landgren et al., 2011, Skibicka et al., 
2011a, Skibicka et al., 2011b).  These converging outcomes strongly support the view that 
GHR receptors modulate reinforcement/reward function.
  
 
* Part of this chapter is reprinted with permission from “Attenuation of cocaine-induced locomotor sensitization 
in rats sustaining genetic or pharmacologic antagonism of ghrelin receptors” Clifford, PS, Rodriguez, J, Schul, 
D, Hughes, S, Kniffin, T, Hart, N, Eitan, S, Brunel, L, Fehrentz, JA, Martinez, J, Wellman, PJ, 2011. Addiction 
Biology 17(6):956-63, Copyright 2011 by Wiley. 
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CHAPTER V 
EXPERIMENT 3:  EFFECT OF GHRELIN RECEPTOR KNOCKOUT ON COCAINE- 
INDUCED LOCOMOTOR SENSITIZATION* 
 
Background 
The rationale for these next two experiments is the same as in the first two 
experiments with a change to the genetic knockout strategy for inactivation of ghrelin 
signaling.  Ghrelin inactivation strategies include immunosuppression (Lu et al., 2009), RNA 
silencing (Shrestha et al., 2009) GHS-R antagonists (Halem et al., 2004, Abizaid et al., 
2006b), and gene knockout strategies, primarily in mice (Abizaid et al., 2006b, Sun et al., 
2008).  Few studies have been done in GHS-R knockout rats.  The next two experiments 
should provide a convergence of the pharmacological antagonism and genetic knockout 
methods in rats.  This experiment considered the impact of genetic ablation of GHS-Rs on 
the development of locomotor sensitization induced by daily administration of COC in rats. 
COC seems to produce its locomotor effects through activation in the NAC (Sellings 
et al., 2006) where GHS-Rs are present (Dickson et al., 2010).  If development of those 
receptors is prevented through genetic knockout, the expected result would be that 
development of locomotor sensitization due to COC would be diminished in rats sustaining 
GHS-R knockout. 
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Experimental Procedures 
Subjects 
The subjects of this experiment were 24 adult male FHH rats described above (see 
General Methods), obtained from (PhysGen Program in Genomic Applications) weighing 
275-300 g at the start of the experiment. 
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Figure 8. Behavioral Analysis of Experiment 3:  Effect of ghrelin receptor 
knockout on COC- induced locomotor sensitization. 
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Behavioral Analysis 
 Animals were separated into WT and GHS-R (-/-) groups based on genotype.  On two 
consecutive days, the rats were adapted to the locomotion chambers for 45 min per day. On 
the next three days, the rats were placed in the chamber for 15 min, removed and injected 
with 0.9% saline and then placed back into the chambers for 45 min. Test animals within 
each group were then randomly assigned to receive intraperitoneal (i.p) injections of either 
vehicle (0.9% saline) or 10.0 mg/kg COC hydrogen chloride for 14 successive days, thus 
forming four test groups: WT/vehicle (n=4), WT/COC (n=7), GHS-R (-/-)/vehicle (n=5) and 
GHS-R (-/-)/ COC (n=8).  Few rats were available for the study and so a decision was made to 
increase the group size for the COC treatment group.  During sensitization testing, animals 
were placed in their respective test chambers for a 15 min baseline-recording period prior to 
receiving either a vehicle or COC injection.  Rats were then placed back in the chamber 
immediately following injection, at which time recording continued for another 45 min (see 
Figure 8). 
 
Data Analysis 
 The overall design of the study was a split-plot (mixed) factorial design consisting of 
between-group factors of GHR receptor status (WT versus GHS-R (-/-)) and COC exposure 
(vehicle versus 10 mg/kg COC) and a within-group factor of day (blocks 1-7 were formed 
using averages of 2 days total distance data).   Because the treatment means and variances 
were proportional, the total distance traveled scores were subjected to a log transformation 
(Kirk, 1982).  Statistical significance was deemed to be p < 0.05 and the Bonferroni 
procedure was used to examine mean group differences.  
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Results 
A two-way ANOVA revealed no significant (p > at least 0.156) effect of GHR 
receptor status, COC exposure nor an interaction among these factors on locomotion scores 
Figure 9. Impact of GHS-R KO on cocaine locomotor sensitization.  
Mean group total changes in total distance traveled scores (cm/45 min) for 
WT and GHS-R (-/-) (KO) rats injected with vehicle on Day 0 and then with 
either vehicle (VEH) or 10 mg/kg COC just prior to the 45 min test period on 
days 1-14.  The lines above each symbol represent the S.E.M.   The star (*) 
indicates a significant (p < 0.05) difference between the respective Veh and 
COC groups.   WT/vehicle (n=4), WT/cocaine (n=7), GHS-R (-/-)/vehicle 
(n=5) and GHS-R (-/-)/ cocaine (n=8).  
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after vehicle (block 0 in Figure 9).  Although there were no initial differences between the 
WT and GHS-R (-/-)  groups treated with vehicle, these groups diverged over the 7 blocks 
such that by the last block, the GHS-R (-/-)  rats treated with vehicle showed significantly less 
locomotion than did the WT rats treated with vehicle.  A two-way ANOVA for the data on 
block 7 was computed using change in locomotion from respective baselines.  This ANOVA 
revealed a significant effect of COC exposure (F(1,20) = 129.1, p < 0.0001), a significant 
effect of GHR gene status (F(1,20) = 15.6, p < 0.0001), and a significant interaction between 
COC exposure and GHR gene status (F(1,20) = 4.1, p < 0.05).  The latter interaction 
reflected the fact that the difference in locomotion scores between the WT and GHS-R (-/-) 
rats during the last block relative to baseline was significantly larger in the COC exposure 
condition than in the vehicle treatment condition.  
 
Discussion 
 In an earlier study, it was noted that rats sustaining mutation of the GHS-R resulting 
in a functional ablation of that receptor do not overeat when given systemic ghrelin injections 
(Figure 10)  and show diminished locomotor sensitization to daily injections of COC, data 
from (Clifford et al., 2012).  Similarly, Abizaid and colleagues noted that ghrelin knockout 
mice exhibit diminished locomotor sensitization to COC (Abizaid et al., 2011).  Collectively, 
these studies suggest that GHS-Rs play a prominent role in the development of behavioral 
sensitization to psychostimulants.  Moreover, the present results extend earlier studies in 
which GHS-Rs were noted to be required for the induction of hyper locomotion to COC, to 
amphetamine, and to ethanol (Jerlhag, 2008, Abizaid, 2009, Jerlhag et al., 2009, Jerlhag et 
al., 2010, Jerlhag and Engel, 2011).   
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The key outcome of this experiment was that GHS-R (-/-) rats exhibited attenuated 
development of COC sensitization over a 14 day exposure period (see Figure 9).  This 
outcome indicates that activation of GHR receptors plays a modest role in the development 
of COC sensitization.  The blunted development of COC locomotor sensitization reported 
herein parallels a recent study by Jerlhag (Jerlhag et al., 2010) in which administration of a 
GHS-R antagonist attenuated the acute hyper locomotion induced by the psychostimulants 
COC as well as amphetamine; reduced the increase in accumbens DA produced by COC and 
Figure 10.  Changes in food intake in WT and GHS-R
(-/-) 
rats after 
ghrelin.  Mean food intakes in grams over a one hour period following 
injection of vehicle or 15 nMol ghrelin in WT and GHS-R (-/-) rats.  The lines 
above each bar represent the S.E.M.  WT rats responded to ghrelin with a 
significant increase in food intake compared to vehicle whereas the GHS-R (-/-
) rats did not (Data unpublished). The star (*) indicates a significant (p < 
0.05) difference between the respective groups.    
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most importantly attenuated COC-induced CPP.  In contrast to the impact of inhibition of 
GHR signaling on COC behavioral function, our earlier laboratory studies showed that 
administration of GHR facilitates COC-induced hyper locomotion and COC-induced CPP 
(Wellman et al., 2005, Davis et al., 2007, Wellman et al., 2008b). 
A more general role for GHRs in brain reinforcement is also indicated by recent 
studies in which pharmacological inactivation of GHS-Rs attenuates the CPP induced by 
ethanol (Jerlhag et al., 2009) whereas genetic ablation of GHRs attenuates the CPP induced 
by ingestion of a high-fat diet (Perello et al., 2010).  The converging outcomes of this 
experiment and experiment 1 strongly support the view that GHR receptors modulate DA 
function and drug-induced reinforcement/reward.    
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CHAPTER VI 
EXPERIMENT 4:  EFFECT OF GHRELIN RECEPTOR KNOCKOUT ON NICOTINE- 
INDUCED LOCOMOTOR SENSITIZATION 
 
Background 
The background for this experiment is identical to that of experiment 2 for the 
rationale behind using NIC, and is identical to that of experiment 3 for the rationale for using 
GHS-R knockout.   This experiment considered the impact of genetic ablation of GHS-Rs on 
the development of locomotor sensitization induced by daily administration of NIC in rats. 
Just as in the second experiment, NIC seems to produce its effects through the VTA 
where a large number of GHS-Rs are present (Abizaid, 2009).  If activation of those 
receptors is prevented through genetic knockout, the expected result would be that locomotor 
sensitization due to NIC would be diminished in rats sustaining GHS-R knockout and to an 
even greater degree than seen in COC-induced locomotor sensitization.  
 
Experimental Procedures 
Subjects 
The subjects of this experiment were 27 adult male FHH rats described above, 
obtained from (PhysGen Program in Genomic Applications) weighing 275-300 g at the start 
of the experiment. 
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Behavioral Analysis 
 Animals were separated into WT and GHS-R (-/-) groups based on genotype.  On two 
consecutive days, the rats were adapted to the locomotion chambers for 45 min per day. On 
the next three days, the rats were placed in the chamber for 15 min, removed and injected 
with 0.9% saline and then placed back into the chambers for 45 min. Test animals within 
each group were then randomly assigned to receive i.p injections of either vehicle (0.9% 
Figure 11.  Behavioral Analysis of Experiment 4:  Effect of ghrelin receptor 
knockout on NIC- induced locomotor sensitization. 
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saline) or subcutaneous (s.c.) injections of 0.4 mg/kg NIC hydrogen tartrate for 10 successive 
days, thus forming four test groups: WT/vehicle (n=4), WT/NIC (n=8), GHS-R (-/-)/vehicle 
(n=4) and GHS-R (-/-)/ NIC (n=11).  There were once again a limited number of animals 
available so a decision was made to increase the group size of the NIC treatment group.  
During sensitization testing, animals were placed in their respective test chambers for a 15 
min baseline-recording period prior to receiving either a vehicle or NIC injection.  Rats were 
then placed back in the chamber immediately following injection, at which time the room 
lights again were turned off and recording continued for another 45 min (see Figure 11). 
 
Results 
A two-way ANOVA revealed no significant (p > at least 0.245) effect of GHR 
receptor status, NIC exposure nor an interaction among these factors on locomotion scores 
after vehicle (day 0 in Figure 12).  A two-way ANOVA for the data on day 9 revealed a 
significant effect of NIC exposure (F(1,23) = 19.75, p < 0.05), GHR gene status (F(1,23) = 
7.71, p < 0.05), and interaction between NIC exposure and GHR gene status (F(1,23) = 5.86, 
p < 0.05).  These interactions reflected that the difference in locomotion scores between the 
WT and the GHS-R (-/-) rats during those days relative to baseline was significantly larger in 
rats receiving NIC than in rats receiving vehicle.  ANOVA for day 10 showed similar 
significant effects of NIC exposure (F(1,23) = 21.70, p < 0.05), GHR gene status (F(1,23) = 
9.48, p < 0.05), but not an interaction between NIC exposure and GHR gene status (F(1,23) = 
3.73, p < 0.07).  
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Figure 12. Impact of GHS-R KO on NIC locomotor sensitization.  The 
results show that WT-Vehicle rats exhibit stable locomotion scores across 
the 10-day testing period.  In contrast, WT-NIC rats were sensitized to 
daily NIC treatment over the testing period.  GHS-R (-/-) rats and WT rats 
treated with vehicle did not show any differences in baseline locomotion.  
Importantly, GHS-R (-/-) rats treated with NIC (0.4 mg/kg) show less 
sensitization over the test period in contrast to those rats in the WT-NIC 
condition.  WT/vehicle (n=4), WT/NIC (n=8), GHS-R (-/-)/vehicle (n=4) 
and GHS-R (-/-)/ NIC (n=11).  The star (*) indicates a significant (p < 
0.05) difference between WT/NIC and KO/NIC.  The (#) indicates a 
significant (p < 0.05) difference between KO/NIC and KO/Veh. 
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Discussion 
The key outcome of this experiment was that GHS-R (-/-) rats exhibited attenuated 
development of NIC sensitization over a 10 day exposure period.  This outcome indicates 
that activation of GHR receptors plays a role in the development of NIC sensitization.  The 
blunted development of NIC locomotor sensitization here supports experiment 2, which 
showed pharmacological antagonism of GHS-Rs attenuated the development of NIC 
locomotor sensitization.  The converging outcomes of this experiment and experiment 3 
strongly support the view that GHS-Rs modulate DA function and drug-induced 
reinforcement/reward particularly for NIC.  
  
 
* Part of this chapter is reprinted with permission from “Brain reinforcement system function is ghrelin 
dependent: studies in the rat using pharmacological fMRI and intracranial self-stimulation” Wellman, PJ, 
Clifford, PS, Rodriguez, JA, Hughes, S, Di Francesco, C, Melotto, S, Tessari, M, Corsi, M, Bifone, A, Gozzi, 
A, 2011. Addiction Biology, 17(5):908-19, Copyright 2011 by Wiley. 
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CHAPTER VII 
EXPERIMENT 5:  EFFECT OF JMV 2959 ON NICOTINE-ENHANCED 
INTRACRANIAL SELF-STIMULATION* 
 
Background 
The next two experiments should provide a convergence of the pharmacological 
antagonism and genetic knockout methods in rats.  Examining locomotor sensitization gives 
us a good idea about the stimulatory effects of psycho-stimulants.  However, it doesn’t 
provide as much information into the rewarding effects of psycho-stimulants that a drug self-
administration method gives us.  Few studies have been done relating ghrelin to drug self-
administration.  Serum levels of ghrelin have been shown to rise preceding periods of 
reinstatement for COC (Tessari et al., 2007); these increases significantly predict COC 
reinstatement.  Preliminary studies from this lab have suggested that JMV 2959 suppresses 
both COC, as well as NIC self-administration (Rodriguez, unpublished data).  There are other 
ways to look at reward other than looking at how drugs are self-administered.  It has been 
demonstrated that electrical stimulation of the brain can result in rewarding effects (Olds and 
Milner, 1954).  Many drugs of abuse facilitate electrical stimulation of the MFB, and this 
electrical stimulation is sensitive to reinforcement (i.e. increased by hunger, decreased by DA 
antagonists (Wise, 1996).  There are many methods for investigating ICSS, but rate-
frequency, described below, is likely the most useful. 
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The construct shown in Figure 13 details what the results should look like in the ICSS 
paradigm.  The middle curve, with circles as data points, is an example of the vehicle 
baseline responding.  The upper curve, with triangles as data points, shows what is expected 
to happen if a drug is administered that facilitates the rewarding effects of the electrical 
stimulation.  This is a leftward shift in the rate-frequency curve where the 50% response rate 
is reached at a lower frequency than is required in the vehicle condition and the 100% 
response rate exceeds the rate seen in the vehicle group.  The lower curve, with squares as  
Figure 13.  Theoretical ICSS Construct 
57 
 
 
Figure 14.  Impact of JMV 2959 and cocaine on rate-frequency responding 
in ICSS.  The results show rate frequency curves for rats treated with vehicle, 
cocaine (5 mg/kg), JMV 2959 (6 mg/kg) or a combined pretreatment of JMV 
2959 and cocaine. Cocaine both increased the 100% response rate and induced a 
slight left-ward shift of the curve (consistent with augmented reinforcement).  In 
contrast, pretreatment with JMV 2959 reversed the left-ward shift and generally 
suppressed ICSS responding.  JMV alone did not significantly alter responding.  
Data unpublished. 
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data points, shows what should happen if a drug is administered that attenuates the rewarding 
effects of the electrical stimulation.  This is called a rightward shift in the rate-frequency 
curve the 50% response rate of the vehicle group is never reached and the 100% response 
rate falls far short of the rate seen in the vehicle group.In an ICSS task like the one performed 
here in the next two experiments, rats press a lever for a pleasurable electrical stimulation of 
their brain at varying frequencies.  Infusion of ghrelin causes a rightward shift in responding 
(unpublished data, Kniffin thesis).  In a recent experiment, rats were trained and tested in the 
same paradigm with COC being the drug tested instead of NIC.  COC both increased the 
100% response rate and induced a slight left-ward shift of the curve (consistent with 
augmented reinforcement).  In contrast, pretreatment with JMV 2959 reversed the left-ward 
shift and generally suppressed ICSS responding.  JMV alone did not significantly alter 
responding (see Figure 14). 
This experiment considered the impact of NIC and JMV 2959 on ICSS responding, 
both separately and in combination.  Since NIC and COC facilitate electrical stimulation in 
the MFB, the expected result would be an effect similar to what was seen with COC (Figure 
14).   
 
Experimental Procedures 
Subjects 
The subjects of this experiment were 5 adult male Sprague-Dawley rats obtained from 
Harlan (Houston, Texas) weighing 250-275 g at the start of the experiment. 
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Behavioral Analysis 
 After recovery from surgery, each rat was shaped to lever-press for rewarding brain 
stimulation on a fixed ratio-1 schedule. During shaping, current intensity was systematically 
increased until a minimum rewarding current (a current sufficient to elicit lever responding) 
is reached (typically between 50-150 μA). Once the lever-pressing behavior is acquired, 
Figure 15.  Behavioral Analysis of Experiment 5:  Effect of JMV 2959 on 
NIC-enhanced intracranial self-stimulation 
60 
 
animals were run through 75 min baseline trials consisting of five separate 15-min passes. 
During each 15-min pass, the intensity was kept constant while the frequency of stimulation 
was lowered each min from 141 Hz to 28 Hz (decreasing in 0.05 log units).  During testing, 
each rat was run multiple trials on separate days and was injected (i.p.) with either vehicle, 
NIC (0.25 mg/kg), or a combination of JMV 2959 (3 mg/kg) and NIC (0.25 mg/kg).  JMV 
2959 was injected 20 min before the beginning of each trial and vehicle and NIC were both 
injected 5 min before the beginning of each trial.  Two days of vehicle trials were interposed 
between each drug trial (see Figure 15).  The number of lever-presses per min was recorded 
for each rat throughout each 75 min trial. 
 
Data Analysis 
Data from the first pass was discarded for each daily test (Carlezon and Chartoff, 
2007).  For each rat and session, the total number of responses, rate-frequency curve, 
maximal response rate (100% response rate), 50% response rate, and threshold (frequency 
which produced 50% response rate) was computed using the responses from the last 4 daily 
passes.  Maximal response rate, 50% response rate, and threshold were analyzed.  
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Results 
 Relative to vehicle condition, NIC slightly increased the response rate and shifted the 
curve to the left (see Figure 16).  Pretreatment with JMV 2959 suppressed responding in NIC 
treated rats relative to the vehicle condition. Analysis of the 100% response rate did not show 
a significant increase in responding in NIC treated rats compared to vehicle (t(8) = -1.358, p 
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Figure 16.  Impact of JMV 2959 and NIC on rate-frequency responding in ICSS.  
The results show rate frequency curves for rats treated with vehicle, NIC (0.25 mg/kg) or 
a combined pretreatment of JMV 2959 and NIC. NIC both increased the 100% response 
rate and induced a slight left-ward shift of the curve (consistent with augmented 
reinforcement).  In contrast, pretreatment with JMV 2959 reversed the left-ward shift and 
generally suppressed ICSS responding.  N=5. 
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= 0.21) but showed a significant decrease in responding in rats given JMV 2959 and NIC 
compared to vehicle rats (t(8) = 5.79, p < 0.001).  Analysis of the 50% response rate showed 
a significant increase in responding following NIC administration compared to vehicle (t (8) 
= -3.104, p < 0.05).  Analysis of the JMV 2959 with NIC condition was not possible at the 
50% rate because there was no responding and therefore there was no variability.  All 
electrode placements were within the lateral hypothalamus between 1.9 and 3.72 mm 
posterior to bregma. 
 
Discussion 
In experiment 5, NIC increased the 50% response rate, slightly increased the 100% 
response rate and induced a slight left-ward shift of the curve (consistent with augmented 
reinforcement; Figure 16).  This is consistent with an earlier experiment in which COC 
increased the 50% and 100% response rate and induced a slight left-ward shift of the curve in 
the same paradigm.  In contrast, pretreatment with JMV 2959 reversed the left-ward shift in 
both the NIC and COC paradigms and generally suppressed ICSS responding.  The 
experiment presented here looks at ICSS at low intensity, but it is as yet unclear whether 
increasing the current intensity would be sufficient to return ICSS responding to baseline or 
above in rats pretreated with JMV 2959 and challenged with NIC.
  
 
* Part of this chapter is reprinted with permission from “Brain reinforcement system function is ghrelin 
dependent: studies in the rat using pharmacological fMRI and intracranial self-stimulation” Wellman, PJ, 
Clifford, PS, Rodriguez, JA, Hughes, S, Di Francesco, C, Melotto, S, Tessari, M, Corsi, M, Bifone, A, Gozzi, 
A, 2011. Addiction Biology, 17(5):908-19, Copyright 2011 by Wiley. 
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CHAPTER VIII 
EXPERIMENT 6: EFFECT OF GHRELIN RECEPTOR KNOCKOUT ON 
INTRACRANIAL SELF-STIMULATION* 
Background 
 There are two main methods of inactivating the ghrelin system.  One approach is 
through the use of GHS-R antagonists, such as JMV 2959, which has been discussed earlier.   
The other primary method of inactivating the ghrelin system is to genetically knockout the 
development of GHS-Rs.  The rationale for looking at ICSS is described in section 1 of 
chapter VII.  This experiment considered the impact of genetic ablation of GHS-Rs on ICSS 
responding. 
 
Experimental Procedures 
Subjects 
 The subjects of this experiment were 11 adult male FHH rats described above, 
obtained from (PhysGen Program in Genomic Applications) weighing 275-300 g at the start 
of the experiment.  Subjects were housed according to the same procedures listed in chapter 
II. 
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Behavioral Analysis 
 Animals were separated into WT (n=5) and GHS-R(-/-) (n=6) groups based on 
genotype.  After recovery from surgery, each rat was shaped to lever-press for rewarding 
brain stimulation on a fixed ratio-1 schedule. During shaping, current intensity was 
systematically increased until a minimum rewarding current (a current sufficient to elicit 
lever responding) is reached (typically between 50-150 μA). Once the lever-pressing 
behavior is acquired, animals were run through 75 min baseline trials consisting of five 
separate 15-min passes (see Figure 17). During each 15-min pass, the intensity was kept 
Figure 17.  Behavioral Analysis of Experiment 6: Effect of ghrelin receptor 
knockout on intracranial self-stimulation 
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constant while the frequency of stimulation was lowered each min from 141 Hz to 28 Hz 
(decreasing in 0.05 log units). 
Data Analysis 
Data from the first pass was discarded for each daily test (Carlezon and Chartoff, 
2007).  For each rat and session, the total number of responses, rate-frequency curve, 
maximal response rate (100% response rate), 50% response rate, and threshold (frequency 
which produced 50% response rate) were computed using the responses from the last 4 daily 
passes.  Maximal response rate, 50% response rate, and threshold were analyzed. 
 
 
 
 
 
 
 
 
 
Figure 18. Typical  ICSS 
Electrode Placements.  All 
electrode placements were 
within the lateral hypothalamus 
between 1.9 and 3.72 mm 
posterior to bregma (plates 
derived from Paxinos and 
Watson (2006). 
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Results 
 In this experiment, GHS-R(-/-) rats were used to investigate whether GHR directly 
influences the functional activity of brain reinforcement circuits. This issue was addressed by 
examining the reinforcing action of ICSS in wild-type (WT) and GHS-R(-/-) rats.   
Rats normally rapidly acquire ICSS responding at stimulation intensities of 75-100 
µA for placements within the lateral hypothalamus (see Figure 18) (Burkey and Nation, 
Figure 19.  Impact of GHS-R KO on rate-frequency responding in ICSS.   Rate 
frequency curves for GHS-R(-/-) rats (N=6) and WT rats (N=5) as a function of 
stimulation intensity.  Panel A:  WT rats tested at 75 µA and GHS-R(-/-) rats tested at 
300 µA show similar rate frequency curves.  WT- and GHS-R(-/-) rats tested at 300 uA 
were not significantly different in terms of total responses or 50% threshold 
responses. When GHS-R(-/-)  rats were tested at 75 uA, the rats did not lever press for 
ICSS (and thus the error bars were zero).  Panel B:  GHS-R(-/-) rats tested at 100 µA 
fail to respond for ICSS, whereas WT rats show a typical rate frequency curve.  
Calculation of threshold response was not possible for GHS-R(-/-) rats tested at 100 
µA. WT (n=5) and GHS-R(-/-) (n=6). 
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1994).  In the present study, GHS-R(-/-)  rats failed to acquire ICSS at stimulation intensities 
of 75-100 µA during our initial shaping procedure, but did acquire responding when intensity 
was increased to 300 µA.  Figure 19 depicts the rate-frequency curves for GHS-R(-/-) rats 
(tested at 300 µA) versus WT rats tested at 75 µA.  These curves were mostly overlapping 
suggesting that GHS-R(-/-) rats show the same general function (i.e. similar total responses at 
the higher stimulation frequencies and a systematic decrease in response rate as stimulation 
frequency is decreased) but at different stimulation intensities.  At the end of rate frequency 
testing, the two groups were retested at a common stimulation intensity of 100uA.  As can be 
seen in Figure 19, the GHS-R(-/-) rats failed to respond for ICSS to any frequency, when 
tested at 100 µA.  All electrode placements were within the lateral hypothalamus between 1.9 
and 3.72 mm posterior to bregma (see Figure 18). 
 
Discussion 
 In this experiment, GHS-R(-/-) rats failed to acquire ICSS at stimulation intensities (~ 
75 µA) sufficient to motivate ICSS in WT rats.  These GHS-R(-/-) rats only acquired the ICSS 
response when the current intensity was increased to more than 300 µA.  After the intensity 
was raised to sufficient intensities, the overall rate-frequency curve of the null rats was 
similar to the curve seen in WT rats (see Figure 19).  Following rate-frequency testing, the 
GHS-R(-/-) rats were shifted back to an intensity of 100 µA, at which point, ICSS responding 
ceased at all frequencies.  This suggests that the GHS-Rs may not be required for ICSS 
responding, but does strongly suggest a facilitative role for these receptors in ICSS.  One 
explanation for this outcome is that the stimulating electrodes employed in this experiment 
were located within the MFB, at the level of the lateral hypothalamus, and that ICSS of this 
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site activated DA fibers coursing from the VTA to the NAcc.  GHS-Rs have a marked 
constitutive action (Petersen et al., 2009) which would be expected to provide activation of 
brain neurons in the absence of ghrelin.  Ablation of this facilitative action on VTA DA 
activity would in turn be expected to diminish ICSS function.  Non-dopaminergic factors 
may be involved since there are relatively few DA fibers within the MFB (Yeomans, 1989, 
Wise, 2002, 2004) and by that ICSS of the lateral hypothalamus induces Fos formation in 
dopaminergic and non-dopaminergic brain sites, such as the substantia nigra, the raphe nuclei 
and the locus coeruleus (Ishida et al., 2001) as well as the VTA.  Another explanation for this 
outcome could be that the GHS-R(-/-) rats had developed brain structures differently, or failed 
to develop them fully, due to a lifelong absence of GHS-Rs.  It is, as yet, unclear what the 
scope of differences that occur in the absence of GHS-Rs compared to WT rats.  It could also 
be that once the intensities were ramped up so high, the stimulating pulses could be affecting 
a larger area thus stimulating surrounding tissues. 
The ENU-based mutation of the GHS-R (resulting in a truncated GHS-R protein 
sequence) is a relatively novel null model of GHS-R function.  As mentioned before, GHS-
R(-/-) rats fail to overeat in response to systemic injection of acylated GHR, whereas WT rats 
significantly increase their food intakes (Clifford et al., 2012).  As noted in the previous 
experiments, there was an attenuated development of locomotion to daily injection of 10 
mg/kg (i.p.) COC in both GHS-R(-/-) rats, as well as rats that were pretreated with JMV 2959, 
a pharmacological antagonist of the GHS-R (Moulin et al., 2007a, Salome et al., 2009b).  
These results suggest a key role for GHS-Rs in the development of locomotor sensitization, 
which is consistent with a role for GHS-Rs in reinforcement processes. A more general role 
for GHS-Rs in brain reinforcement is also indicated by recent studies in which 
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pharmacological inactivation of GHS-Rs attenuates the hyperlocomotor effects, the release of 
accumbens DA and the CPP induced by alcohol (Jerlhag et al., 2009), NIC (Jerlhag and 
Engel, 2011), and amphetamine and COC (Jerlhag et al., 2010).  With regard to ethanol, 
there is evidence that blockade of GHS-Rs diminishes alcohol consumption and alcohol self-
administration (Landgren et al., 2012) and that genetic variation of the GHS-R can be 
associated with human alcohol overconsumption (Landgren et al., 2009, Landgren et al., 
2010).  Finally, GHS-Rs modulate the reinforcing effects that accrue to consumption of food.  
Systemic GHR administration increases food consumption and food reward (Disse et al., 
2010, Dickson et al., 2011, Skibicka et al., 2011b) while blockade of GHS-Rs can suppress 
consumption and associated preference for palatable foods including sweets and foods high 
in fat (Egecioglu et al., 2010, Perello et al., 2010, Skibicka et al., 2011b).  Collectively, these 
studies strongly support the importance of GHS-R signaling for reinforcement; whether that 
reinforcement is associated with eating, drug ingestion or ICSS. 
  
 
* Part of this chapter is reprinted with permission from “Brain reinforcement system function is ghrelin 
dependent: studies in the rat using pharmacological fMRI and intracranial self-stimulation” Wellman, PJ, 
Clifford, PS, Rodriguez, JA, Hughes, S, Di Francesco, C, Melotto, S, Tessari, M, Corsi, M, Bifone, A, Gozzi, 
A, 2011. Addiction Biology, 17(5):908-19, Copyright 2011 by Wiley. 
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CHAPTER IX 
GENERAL DISCUSSION AND CONCLUSION* 
 
Experiment 1 examined the development of locomotor sensitization induced by 
repeated administration of 10 mg/kg COC in rats for which GHR receptors were subject to 
pharmacological inactivation via a 6 mg/kg dose of JMV 2959.  These results in which 
inactivation of GHS-Rs diminished the development of COC sensitized locomotion (see 
Figure 5) are consistent with other studies in which functional GHS-R activity is key to COC 
stimulated locomotion (Abizaid et al., 2006b, Jerlhag et al., 2006, Blum et al., 2009).  This 
result indicates that pharmacological inactivation of GHS-Rs attenuates the development of 
COC locomotor sensitization.  This effect was not evident during acute administration of 
COC, but rather was revealed after chronic COC exposures while the animals were in the 
process of developing sensitization.  One problem with this experiment is the lack of 
variation in the dosages.  The 10 mg/kg dose of COC was chosen because in past studies it 
produced the highest level of responding without causing any aversion, but other doses of 
JMV could be used to further the power of this experiment.  
 Experiment 2 considered the development of locomotor sensitization induced by 
repeated administration of 0.4 mg/kg NIC in rats for which GHR receptors were antagonized 
via JMV 2959 (Moulin et al., 2007a, Salome et al., 2009b).  JMV 2959 significantly 
attenuated the development of hyperlocomotion to daily injections of 0.4 mg/kg NIC.  
However, JMV 2959 administered by itself was not sufficient to reduce locomotion at 3 
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mg/kg, and the 6 mg/kg dose reduced locomotion only a modest amount (see Figure 7).  As 
mentioned before, this outcome is similar to another recent study done in Long-Evans rats 
showing that 6 mg/kg JMV 2959 produced behavior disruptions, but not at lower doses such 
as 1, 2 or 3 mg/kg JMV 2959 (Landgren et al., 2012).  In experiment 2, both 3 and 6 mg/kg 
JMV 2959 produced similar attenuation of the development of NIC-induced hyper 
locomotion.  These results suggest that the attenuation of locomotor sensitization to NIC is 
not simply JMV 2959 disrupting baseline locomotion by itself.  The blunted development of 
NIC locomotor sensitization reported here is similar in direction to what is seen in 
experiment 1 (compare Figures 5 and 7) in which the same 6 mg/kg JMV 2959 dose was 
noted to attenuate the sensitization induced by daily injection of 10 mg/kg COC in rats 
(Clifford et al., in press).   
 
 
 
 
 
 
 
 
Figure 20.  Simplified GHS-R functionality circuit 
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 Interestingly, the effect that JMV 2959 has on NIC induced locomotor sensitization is 
more pronounced than its effect on COC induced locomotor sensitization.  This might be due 
to the fact that COC and NIC produce sensitization via different pathways.  COC acts 
through the NAC via blockade of reuptake to produce locomotor effects whereas NIC acts to 
increase DA fiber firing rate within the VTA, which in turn induces DA activation in the 
VTA (see Figure 20).   There is a heavy concentration of GHS-Rs within the VTA but these 
are sparse within the NAC.  While it may be difficult to infer functional activity from relative 
receptor number, one possible explanation for this pattern of results is that GHS-Rs have a 
greater linkage to NIC-induced locomotor activation and thus JMV 2959 has a greater impact 
than it does for COC-induced locomotion (which lies within the NAC with relatively few 
GHS-Rs).  
In experiment 3, rats sustaining GHS-R knockout exhibited attenuated development 
of COC sensitization.  This indicates that activation of GHS-Rs plays at least a modest role in 
the development of COC sensitization.  The blunted development of COC locomotor 
sensitization reported herein parallels the results of experiment 1 where JMV 2959 
diminished COC induced locomotor sensitization (see Figure 9).  This outcome is similar to 
the outcome of a recent study by Jerlhag (Jerlhag et al., 2010) in which administration of a 
GHS-R antagonist attenuated the acute hyper locomotion induced by COC.  Considering that 
both pharmacological antagonism and genetic ablation of GHS-Rs both diminish COC 
induced locomotor sensitization, experiments 1 and 3 together provide a convergence of 
methods to inactivate ghrelin signaling. 
 In experiment 4, rats sustaining GHS-R knockout exhibited attenuated development 
of NIC sensitization (see Figure 12).  This suggests that activation of GHS-Rs plays a role in 
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the development of NIC sensitization.  This outcome is similar to what is shown in 
experiment 2 where JMV 2959 attenuated NIC induced locomotor sensitization (compare 
Figures 9 and 12).  Since experiments 2 and 4 demonstrate that pharmacological antagonism 
and genetic ablation of GHS-Rs attenuates the development of NIC-induced locomotor 
sensitization, once again there is a convergence of methods to inactivate ghrelin signaling 
and of outcomes.  This convergence makes the data that much more compelling.  Comparing 
the outcomes of experiments 1 and 2 showed a greater impact of JMV 2959 on NIC induced 
locomotor sensitization than COC induced locomotor sensitization.  This difference is also 
seen in experiments 3 and 4 showing that genetic ablation of GHS-Rs has a larger impact on 
NIC induced locomotor sensitization compared to COC.  This is also likely due to NIC and 
COC acting through different pathways.  The loss of GHS-Rs in the VTA is greater than the 
loss would be in the NAC which should result in a larger effect, which is shown here.   
 In experiment 5, NIC both increased the 100% self-stimulation response rate and 
induced a slight left-ward shift of the curve (consistent with augmented reinforcement) (see 
Figure 16).  This parallels an earlier experiment in which COC was used in NIC’s place and 
COC also increased the 100% response rate and induced a slight left-ward shift of the curve 
(see Figure 14).  In contrast, pretreatment with JMV 2959 reversed the left-ward shift in both 
the NIC and COC paradigms and generally suppressed ICSS responding.  In this instance, the 
effect was more pronounced in the COC condition compared to NIC (compare Figures 14 
and 16).  This is likely due to electrodes being located within the MFB, and that ICSS of this 
site activated DA fibers coursing from the VTA to the NAC.  
 In experiment 6, rats sustaining GHS-R knockout were unable to acquire ICSS at 
stimulation intensities (~ 75 µA) that are sufficient to motivate ICSS in WT rats (see Figure 
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19).  It was not until the current intensity was ramped up to more than 300 µA that these 
GHS-R(-/-) rats were able to acquired ICSS responding.  After the intensity was raised high 
enough to elicit responding, the overall rate-frequency curve of the null rats was similar to 
the curve seen in WT rats.  Following rate-frequency testing, the GHS-R(-/-) rats were 
returned to an intensity of 100 µA, at which point, ICSS responding ceased at all frequencies.  
This suggests that the GHS-Rs may not be required for ICSS responding, but rather acts in a 
facilitative role for these receptors in ICSS.  Abizaid noted that activation of GHS-Rs 
resulted in more excitability of DA fibers (due to greater glutamate activity) within the VTA 
(and less inhibitory GABA inputs) (Abizaid et al., 2006b).  This could be because the 
stimulating electrodes employed in this experiment were located within the MFB, at the level 
of the lateral hypothalamus, and that ICSS of this site activates DA fibers coursing from the 
VTA to the NAC.  Not all of these reinforcement fibers involve DA (Wellman et al., 2012) 
and it may be possible that with higher current intensities, non-DA fibers (which are not 
influenced by ghrelin or GHS-Rs) are recruited, resulting in ICSS.  Based on the results of 
this experiment, it would be of great interest to see if raising the current intensity of rats 
pretreated with JMV 2959 and challenged with NIC or COC would be sufficient to rescue 
their ICSS responding. 
 Together, these experiments provide a strong basis for the therapeutic effects of GHS-
R antagonism in relation to drug reward.  The important outcome to take away from these 
series of experiments is the consistent suppression of NIC and COC induced locomotion and 
reinforcement by JMV 2959.  The GHS-R knockout studies serve to support and extend the 
studies involving JMV 2959.  It is important to note that JMV 2959 has a consistent profile 
of shutting down the effects of NIC and COC.  Considering the results of experiments 1 and 
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2, JMV 2959 could prove useful in the treatment of addiction, at least in the prevention of 
reinstatement of COC or NIC.  From the data presented here, the impact of GHS-R 
antagonism seems to be greater with NIC rather than COC.  This is quite fortuitous because 
the scope of NIC addiction is far greater than the scope of COC addiction.  The use of JMV 
2959 in the prevention of acquisition of drug abuse is obviously impractical, but it could be 
of use as a counter measure to addiction (i.e., to assist in stopping drug-taking and to prevent 
relapse after drug cessation).  One of the added benefits of JMV 2959 is that it also acts on 
feeding behavior to reduce food intake.  The cessation of smoking has been repeatedly linked 
to an instance of weight gain.  Many female smokers have reported an unwillingness to quit 
smoking if it meant gaining even 5 pounds (Pomerleau, 1986).  JMV 2959 could possibly aid 
in the cessation of smoking while simultaneously reducing food intake and preventing the 
weight gain association with quitting.    
 In the future, it would be important to examine other GHS-R antagonists to see if they 
result in the same attenuations of the development of drug sensitization.  Also, GHS-R 
antagonists that do not cross the blood brain barrier would be useful to look at to block the 
leftward shifts seen in the ICSS experiments to see if the effect is central or peripheral.  Also, 
as touched upon earlier, it would be nice to look at the effects of vagal GHS-Rs.  
Immunization against GHS-Rs might be an avenue of study in the future.  There is already 
work being done with drug immunizations against COC use (Koob et al., 2011), but GHS-R 
inactivation could prove more useful.  Another future study should look at NIC in the 
periphery and JMV 2959 in the VTA to see if it blocks the locomotor effects and the DA 
change in the NAC.  It would also be important to determine if there are gender differences 
with regard to modulation of ghrelin signaling and drug reinforcement. 
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 The first follow up that needs to be addressed, however, is to look at NIC self 
administration in GHS-R(-/-) rats and rats pretreated with JMV 2959 or other GHS-R 
antagonists.  ICSS is a proxy for drug addiction, but the gold standard is drug self-
administration.  There is some preliminary unpublished data from our laboratory showing 
that pretreatment with JMV 2959 inhibits i.v. self-administration of 0.5 mg/kg/infusion of 
COC and to 0.03 mg/kg/infusion of NIC (Rodriguez, 2012, unpublished data).  This needs to 
be extender further with the same conditions presented here.  
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